New substituted azetidinones of the general formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. ##STR1## wherein R4 is (a) ##STR2## or (b) ##STR3## where Rx is carboxy C1-6 alkyl, benzyloxycarbonylC1-3 alkyl, or t-butoxycarbonylC1-3 alkyl,

wherein

Q is a covalent bond or ##STR4## wherein R5 and R6 are each individually C1-3 alkyl or hydrogen,

Y is ##STR5## or a covalent bond.

PTO Wrapper PDF
Dossier Espace Google
Patent
   5591737
Priority
Dec 17 1992
Filed
Dec 16 1993
Issued
Jan 07 1997
Expiry
Jan 07 2014
Inventors
MacCoss, M…
Assg.orig
MERCK & CO…
Assg.curr
Merck Shar…
Entity
Large
Referenced by
11
References
33
Maint.:
all paid
BACKGROUND OF THE IN…
BRIEF DESCRIPTION OF…
DETAILED DESCRIPTION…
EXAMPLE 1
EXAMPLE 2
EXAMPLE 3
EXAMPLE 4
EXAMPLE 5
EXAMPLE 6
EXAMPLE 7
EXAMPLE 8
EXAMPLE 9
EXAMPLE 10
EXAMPLE 11
EXAMPLE 12
Diamine Intermediates
EXAMPLE 13
EXAMPLE 14
EXAMPLE 17 ##STR36##
EXAMPLE 18
EXAMPLE 19
EXAMPLE 20
EXAMPLE 21
EXAMPLE 22
EXAMPLE 23
EXAMPLE 24
EXAMPLE 25
EXAMPLE 26
16. A compound of the formula ##STR59## where n and A are:
______________________________________
n A
______________________________________
2 1 4-morpholinyl,
3 1 --N(CH3)CH2 CH2 N(CH3)2,
4 0 --N(CH3)CH2 CH2 N(CH3)2,
5 0 --N(Et)2,
6 0 --N(CH3)(n-Bu),
7 0 4-methyl-1-piperazinyl,
8 0 --N(CH3)CH2 CH2 N(CH3)CH2 Ph,
9 0 4-cyclopropyl-1-piperazinyl, or
10 0 1-piperazinyl,
11 0 4-(2-hydroxyethyl)-1-piperazinyl, or
12 0 4-morpholinyl.
______________________________________
18. A compound of the formula ##STR61## wherein n, R3 and A are:
______________________________________
n R3 A
______________________________________
2 1 H --N(CH3)CH2 CH2 N(CH3)2,
1
4 0 H --N(CH3)CH2 CH2 N(CH3)2,
8
5 0 H --OCH2 CH2 N(CH3)2,
6 0 H --N(Et)2, or
7 0 H 4-morpholinyl.
______________________________________
17. A compound of the formula ##STR60## wherein n, R2, and A are:
______________________________________
n R2 A
______________________________________
1 1 H 4-morpholinyl,
2 1 H --N(Et)2,
3 1 H --N(CH3)CH2 CH2 N(CH3)2,
1
5 1 CH3 N(Et)2,
6 1 CH3 N(n-Pr)2,
7 0 Et --N(CH3)CH2 CH2 N(CH3)2,
or
8 0 Et --N(CH3)(n-Bu).
______________________________________
19. A compound of the formula ##STR62## where n, R3, R4, and A are:
__________________________________________________________________________
n R3 R4 A
__________________________________________________________________________
1 1 H CO2 H 4-morpholinyl,
2 1 H --CO2 CH2 CH2 N(CH3)2
4-morpholinyl,
3 1 H --CON(CH3)CH2 CH2 N(CH3)2
4-morpholinyl,
4 1 H --OH --N(CH3)CH2 CH2 N(CH3).s
ub.2,
5 1 H OCH3 --N(CH3)CH2 CH2 N(CH3).s
ub.2,
6 0 H --CON(CH3)2
--N(CH3)CH2 CH2 N(CH3).s
ub.2,
7 0 H --CO2 H --N(CH3)CH2 CH2 N(CH3).s
ub.2,
8 0 H --CH2 OH --N(CH3)CH2 CH2 N(CH3).s
ub.2,
9 1 H OCH3 --N(CH3)CH2 CH2 N(CH3).s
ub.2,
10
0 H OCH3 --N(CH3)CH2 CH2 N(CH3).s
ub.2,
11
0 OCH3 H --N(CH3)CH2 CH2 N(CH3).s
ub.2,
12
1 --CH2 OCON(Et)2
CH3 4-morpholinyl,
13
1 --CON(n-Pr)2
CH3 --N(Et)2,
14
1 CON(n-Pr)2
CH3 4-morpholinyl,
15
0 H CN --N(CH3)CH2 CH2 N(CH3).s
ub.2,
16
0 H OEt --N(CH3)CH2 CH2 N(CH3)CH
2 Ph,
17
0 H 2-(4-morpholinocarbonylphenyl)
--N(CH3)CH2 CH2 N(CH3)CH
2 Ph,
18
0 H OCH3 4-methyl-1-piperazinyl,
19
0 H Cl --N(CH3)CH2 CH2 N(CH3).s
ub.2,
20
0 H Cl --N(CH3)CH2 CH2 N(Et)2,
21
0 H Cl --N(CH3)CH2 CH2 N(i-Pr)2
,
22
0 H Cl --N(CH3)CH2 CH2 N(CH3)CH
2 Ph, or
23
0 OCH3 CH3 --N(CH3)CH2 CH2 N(CH3).s
ub.2.
__________________________________________________________________________
22. A compound which is
[S-(R*,S*)]-2-[4-[[4-methylpiperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[ 1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide, or a pharmaceutically acceptable salt thereof.
15. A compound of the formula ##STR58## wherein R is:
-- CH3,
2 4-fluorophenyl,
3 3-chlorophenyl,
4 phenyl,
5 benzyl,
6 H,
7 i-Pr,
8 i-Bu,
9 --CH2 CO2 Et
10 --CH2 CO2 H,
11 Et,
12 Pr,
13 2-pyrimidinyl,
14 --CH2 CH2 OC(O)NHCH3,
15 cyclopropyl, or
16 --CH2 CH2 OH.
23. A pharmaceutical composition for the inhibition of human leukocyte elastase which comprises a nontoxic therapeutically effective amount of a compound which is
[S-(R*,S*)]-2-[4-[[4-methylpiperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[ 1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
11. A compound according to the formula ##STR55## wherein A is:
-- CH2 CH2 N(CH3)2,
2 --CH2 CO2 H,
3 --CH2 --C(O)N(CH2 CH2 OH)2,
4 --CH2 --C(O)N(CH3)CH2 C(O)NH2,
5 --CH2 C(O)NH--C(CH2 OH)3,
6 --CH2 C(O)N(CH3)2,
7 --CH2 CH2 N(CH3)Ac,
10 --CH(CH3)CO2 CH2 Ph,
11 --CH(CH3)CO2 H,
12 --CH(CH3)C(O)N(Et)2,
13 --CH(CH3)CH2 N(CH3)2,
14 --CH2 CH2 CH2 N(CH3)2,
16 --CH2 CH2 N(Et)2,
17 --CH2 CH2 (4--morpholinyl ),
18 --CH2 CH2 CH2 CH2 N(CH3)2,
19 --CH2 C(O)--Pro--NHCH2 Ph,
20 --CH2 C(CH3)2 N(CH3)2,
21 --CH2 CH2 N(i--Pr)2,
23 --CH2 CH2 N(n--Bu)2,
24 --CH2 CH2 CH2 CH2 CH2 CH2 N(CH3)2,
25 --CH2 CH2 (1-piperazinyl),
26 --CH2 CH2 (4-methyl-1-piperazinyl),
28 --CH2 CH2 N(Ph)2,
29 --CH2 CH2 N(CH2 CH═CH2)2,
30 --CH2 CH(Ph)N(CH3)2, or
31 --CH2 CH2 N(CH3)CH2 Ph.
13. A compound of the formula ##STR57## wherein A is
-- N(H2 CH2 OH)2,
2 4-methyl-1-piperazinyl,
3 4-morpholinyl,
4 --NHCH2 CH2 N(CH3)2,
5 --N(CH3)CH2 CH2 N(CH3)2,
6 --NCHC2 CH2 CH2 N(CH3)2,
7 --NHCH2 CH2 --(4-pyridyl),
8 --NHCH2 CO2 H,
9 --NHCH(CH3)CO2 H,
10 --NHCH2 C(O)N(CH2 CH2 OH)2,
11 --N(CH3)CH2 CO2 H,
12 --NHCH(CH3)C(O)N(CH2 CH2 OH)2,
13 --N(CH3)CH2 C(O)N(CH2 CH2 OH)2,
14 --N(CH3)CH2 CH2 --(4-morpholinyl),
15 --N(CH3)CH2 CH2 N(CH2 CH2 OCH3)2,
16 --N(CH3)CH2 CH2 CH2 N(Et)2,
17 --N(CH3)CH2 CH2 CH2 N(CH3)2,
18 --NHCH2 CH(CH3)N(CH3)2,
19 --N(CH3)CH2 CH2 N(i-pr)2,
2-- N(n-pro)2,
21 --N(Et)2,
22 3-chloroanilino-,
23 3-methoxyanilino-,
24 4-fluoroanilino-,
25 --N(CH3)CH2 CH2 CH2 CO2 H,
26 --N(CH3)CH2 CH2 CH2 C(O)NHSO2 Ph,
27 --N(CH3)CH2 CH2 CH2 N(CH3)CH2 Ph,
28 --N(CH3)2,
29 --N(CH3)CH2 Ph,
30 --N(CH3)CH2 CH2 N(CH3)CH2 Ph,
31 --NH--O--CH2 Ph,
32 --N(CH3)(4-carboxyphenyl), or
33 --N(CH3)(4-benzenesulfonylaminocarbonylphenyl).
14. A compound selected from the group consisting of:
(a) [S-(R*,S*)]-2-[4-[[[2-(dimethylamino)ethyl]methyl-amino]carbonyl]-phenoxy] 3,3-diethyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(b) [S-(R*,S*)]-2-[4-[[[2-(dimethylamino)ethyl]methyl-amino]carbonyl]phenoxy]3 ,3-diethyl-N-[1-(3,4-methylenedioxy-phenyl)butyl]-4-oxo-1--azetidine-carbox amide,
(c) [S-(R*,S*)]-2-[4-[[4-methylpiperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N- [1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(d) [S-(R*,S*)]-2-[4-[[4-methylpiperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N- [1-(3,4-methylenedioxy-phenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(e) [S-(R*,S*)]-2-[4-[[4-cyclopropylpiperazin-1-yl]-carbonyl]phenoxy]-3,3-diet hyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(f) [S-(R*,S*)]-2-[4-[[4-cyclopropylpiperazin-1-yl]carbonyl]phenoxy]-3,3-dieth yl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(g) [S-(R*,S*)]-2-[4-[[piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[1-(4-me thylphenyl)butyl]-4-oxo-1-azetidinecarboxamide, or
(h) [S-(R*,S*)]-2-[4-[[piperazin-1-yl]carbonyl]-phenoxy]-3,3-diethyl-N-[1-(3,4 -methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(i) [S-(R*,S*)]-2-[4-[[((2-dimethylamino)ethyl)ethylamino]carbonyl]-phenoxy]-3 ,3-diethyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(j) [S-(R*,S*)]-2-[4-[[((2-diethylamino)ethyl)ethylamino]carbonyl]phenoxy]-3,3 -diethyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(k) [S-(R*,S*)]-2-[4-[[(4-(2-hydroxyethyl))piperazin-1-yl]carbonyl]phenoxy]-3, 3-diethyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(l) [S-(R*,S*)]-2-[4-[[(4-(2-hydroxyethyl))piperazin-1-yl]carbonyl]phenoxy]-3, 3-diethyl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamid e, or
(m) [S-(R*,S*)]-2-[4-[[(4-(ethoxycarbonylmethyl))piperazin-1-yl]carbonyl]pheno xy]-3,3-diethyl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarb oxamide.
21. A compound selected from the group consisting of:
(a) t-Butoxycarbonylmethyl [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl)-4- oxo-2-azetidinyl)oxy)benzoate,
(b) 2-(bis(2-hydroxyethyl)amino)-2-oxoethyl(S-(R*,S*))-4-((3,3-diethyl-1-(((1- (4-methyl-phenyl)butyl)amino)carbonyl)-4-oxo-2-azetidinyl) oxy)benzoate,
(c) 1-methyl-2-oxo-2-(phenylmethyloxy)ethyl (2S-(1(S*),2R*,(R)))-4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)ca rbonyl)-4-oxo-2-azetidinyl)oxy)benzoate,
(d) 1-carboxyethyl [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methyl-phenyl)butyl)amino)carbonyl)-4 -oxo-2- azetidinyl)oxy)benzoate,
(e) 2-(diethylamino)-1-methyl-2-oxoethyl [S-(R*,S,)]-4-((3,3-diethyl-1-(((1-(4-methyl-phenyl)butyl)-amino)carbonyl) -4-oxo-2- azetidinyl)oxy)benzoate
(f) (S(R*,S*))-1-(((4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbony l)-4-oxo-2-azetidinyl)oxy) benzoyl)oxy)acetyl)-L-proline,
(g) [S-(R*,S,)]1-(((4-((3,3-diethyl-1-(((1-(4-methylphenylbutyl)amino)carbonyl )-4-oxo-2-azetidinyl)oxy)benzoyl)oxy)acetyl)-N-benzyl-L-prolinamide,
(h) 2-(dimethylamino)ethyl(S-(R*,S,))-4-((3,3-diethyl-1-(((1-(4-methyl-phenyl) butyl)amino)carbonyl)-4oxo-2-azetidinyl)oxy)benzoate,
(i) 1-Dimethylamino-2-propyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(j) 3-Dimethylamino-1-propyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(k) 2-Diethylaminoethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(l) 2-(1-[4-morpholino]ethyl) [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(m) 4-dimethylaminobutyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(n) 2-dimethylamino-2-methyl-1-propyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(o) 2-(diisopropylamino)ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(p) Benzyl [S-(R*,S,)]-4-[2-[[4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]-car bonyl]-4-oxo-2-azetidinyl]oxy]benzoyl]oxy]-ethyl]-1-piperazinecarboxylate,
(q) 2-(dibutylamino)ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(r) [S-(R*,S*)]-6-(dimethylamino)hexyl4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl) butyl]amino]carbonyl]-4-oxo-2-azetidinyl] oxy]-benzoate,
(s) 2-(4-methyl-1-piperazinyl)ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(t) 2-(diphenylamino)ethyl[S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl) butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoate,
(u) 2-(di-2-propenylamino)ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(v) 2-(dimethylamino)-2-phenylethyl[S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methy l-phenyl)butyl]amino]carbonyl]-4-oxo-2-azetidinyl] oxy]benzoate,
(w) 2-[methyl(phenylmethyl)amino]ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate,
(x) 2-(dimethylamino)ethyl[S,(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl) butyl]amino]carbonyl]-4-oxo-2-azetidinyl] oxy]-2,6-dimethyl-benzoate,
(y) 2-(diethylamino)ethyl[S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)b utyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]-2,6-dimethylbenzoate,
(z) 2-[bis(1-methylethyl)amino]-ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]-2,6-dimethyl-benzoate.
1. A compound of formula (I): ##STR37## or a pharmaceutically acceptable salt thereof wherein: R is C1-6 alkyl;
R1 is C1-6 alkyl or C1-6 alkoxy-C1-6 alkyl;
M is
(1) hydrogen,
(2) C1-6 alkyl,
(3) hydroxy C1-6 alkyl,
(4) halo C1-6 alkyl,
(5) C2-6 alkenyl, or
(6) C1-6 alkoxy-C1-6 alkyl;
Ra and rb are each individually
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(4) carboxy,
(5) C1-6 alkoxy,
(6) phenyl,
(7) C1-6 alkylcarbonyl,
(8) di-(C1-6 alkyl)amino;
(9) hydroxy;
R2 and R3 are each independently
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(4) C1-6 alkoxy,
(5) phenyl,
(6) C1-6 alkylcarbonyl,
(7) aminoC2-3 alkyloxy carbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(8) aminoC2-3 alkylamino carbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(9) hydroxy,
(10) aminocarbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(11) hydroxymethyl,
(12) aminocarbonyloxy C1-3 alkyl, wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(13) cyano,
(14) morpholinocarbonylphenyl,
(15) amino wherein the amino is optionally mono or di substituted with C1-6 alkyl, or
(16) morpholinocarbonyl, with the proviso that R2 and R3 may be joined together to form a methylenedioxy group or a furan ring,
R4 is (a) ##STR38## (b) or ##STR39## where Rx is carboxy C1-6 alkyl, benzyloxycarbonylC1-3 alkyl, or t-butoxycarbonylC1-3 alkyl,
wherein
Q is a covalent bond, or ##STR40## wherein R5 and R6 are each individually C1-3 alkyl or hydrogen,
Y is ##STR41## R12 is hydrogen or C1-3 alkyl; R7 and R8 are each individually
(a) hydrogen,
(b) C1-6 alkyl,
(c) C1-6 alkyloxy C2-3 alkyl,
(d) hydroxy C2-6 alkyl,
(e) polyhydroxyC2-6 alkyl,
(f) carboxamido C1-6 alkyl,
(g) C1-6 alkanoyl,
(h) substituted phenyl or phenyl C1-6 alkyl, wherein the substitutents are X1 and X2 as defined immediately below,
(i) C2-6 alkenyl,
(j) C6-10 cycloalkenyl,
(k) heteroaryl C1-6 alkyl wherein the hetero aryl is selected from pyridinyl, imidazolyl, triazolyl, benzylimidazolyl, and furyl,
(l) carboxy C1-6 alkyl,
(m) carbo C1-6 alkoxy C1-3 alkyl,
(n) phenylsulfonyl,
(o) C1-6 alkylsulfonyl,
(p) benzyloxy,
(q) morpholinyl C1-3 alkylsulfonyl,
(r) tetrahydropyranyl,
(s) aminoC1-3 alkylsulfonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(t) aminocarbonyl wherein the amino is optionally mono or disubstituted with C1-6 alkyl,
(u) aminocarbonyloxyC2-6 alkyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(v) azabicyclo of 7 to 12 atoms,
(w) di C1-3 alkylamino C2-6 alkyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(x) bicycloalkyl of 7 to 12 atoms,
(y) C3-10 cycloalkyl optionally substituted with C1-6 alkyl,
(z) pyrazolidinyl,
(aa) substituted piperidinyl or prrrolidinyl wherein the substitutent is hydrogen, C1-3 alkyl, hydroxy C1-3 alkylbenzyl, carboxamido or amino wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(bb) substituted pyrrolidinyl wherein the substitutent is carboxamido or amino wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(cc) pyrimidinyl,
(dd) phosphonoC1-6 alkyl, or
(ee) α-C1-3 alkyl benzyl or mono or di substituted benzyl or mono or di substituted pyridylmethyl, wherein the substitutents are X1 and X2,
wherein
X1 is
(1) hydrogen,
(2) halo,
(3) C1-6 alkyl,
(4) halo-C1-6 alkyl,
(5) C2-6 alkenyl,
(6) hydroxy-C1-6 alkyl,
(7) C1-6 alkylcarbonyl,
(8) C1-6 alkylcarbonylamino,
(9) CN,
(10) CF3,
(11) CH3 O,
(12) amino wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(13) carboxy, or
(14) phenylsulfonylaminocarbonyl;
X2 is hydrogen, halo or C1-6 alkyl;
n is 1, 2, 3, 4 or 5;
R9 is selected from hydrogen, C1-4 alkyl, and C1-3 alkoxyC2-3 alkyl; or phenyl, phenyl C1-3 alkyl, pyridyl, and pyridyl C1-3 alkyl; R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl, or are together O═; or
wherein
R7 and R8 are joined together with the nitrogen to which they are attached to form mono or di substituted ring selected from
(1) piperidinyl or homopiperdinyl,
(2) piperazinyl,
(3) morpholinyl, thiomorpholinyl or 1,1-dioxo-4-thiomorpholinyl,
(4) pyrroylidinyl,
(5) pyrryl,
(6) imidazolyl,
(7) triazolyl,
(8) saturated azabicyclo of 7 to 12 atoms,
(9) azaspiro having 3 to 9 carbon atoms, said ring being saturated,
(10) tetrazolyl,
(11) pyrazolidinyl,
(12) azetidinyl, or
(13) diazabicyclo ring of 7-12 atoms,
wherein the substitutents are each selected from the group consisting of hydrogen and C1-3 alkyl, benzyloxycarbonyl,phenyl C1-3 alkyl amino carbonyl, hydroxy C1-3 alkyl, C1-6 alkyloxy, C1-4 alkyloxy carbonyl, aminocarbonyl wherein the amino is optionally mono or di substituted with
C1-6 alkyl, and oxo; or
--N(R7)R8 is
--NH--(CH2)3 --C(H)(NH2)--C(O)OH, or
NH2 --(CH2)3 --C(H)(NH)--C(O)OH;
R8 and R9 are joined together to form a mono or di substituted saturated monocyclic ring of 6 to 7 atoms and having two hetero atoms which are the nitrogens to which R8 and R9 are attached; or R9 and R10 are joined together to form a mono or di substituted monocyclic saturated ring of 5 to 7 atoms and having one hetero atom which is the nitrogen to which R9 is attached; or wherein R9 and R12 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R9 is attached; or
wherein R10 and R12 are joined together with the carbons to which they are attached to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 carbon atoms; or
wherein R8 and R11 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R8 is attached, and the substituents are independently selected from hydrogen and C1-3 alkyl.
27. A compound of the formula ##STR64## wherein A is:
-- NHCH2 CH2 N(CH3)2,
2 --NH--CH2 CO2 H,
3 --N(CH3)CH2 CH2 N(CH3)2,
4 --N(Et)CH2 CH2 N(CH3)2,
5 --NHCH2 CH2 N(Et)2,
6 --NHCH2 CH2 -(4-morpholinyl),
7 --N(CH3)CH2 CH2 -(4-morpholinyl),
8 --N(CH3)CH2 CH2 N(CH2 CH2 OCH3)2,
9 --N(CH3)CH2 CH2 N(Et)2,
10 --N(Ph)CH2 CH2 N(CH3)2,
11 --N(CH3)CH2 CH2 CH2 N(CH3)2,
12 --NH CH2 CH2 N(i-Pr)2,
13 --N(CH3)CH2 CH2 N(O)(CH3)2,
14 --N(CH3)CH2 CH2 N(i-Pr)2,
15 --NH--SO2 CH2 CH2 -(4-morpholinyl),
16 --NH--SO2 CH2 CH2 N(CH3)2,
17 --NHCH2 CH2 -(4-imidazolyl),
18 --NHCH2 CH2 -(1-piperidinyl),
19 --N(CH3)CH2 CH2 -(1-piperidinyl),
20 --N(CH3)CH2 CH2 NHCH3,
21 --N(CH3)CH2 CH2 N(CH3)Ac,
22 --NHCH2 CH2 -(1-pyrrolidinyl),
23 --N(CH3)CH2 CH2 -(1-pyrrolidinyl),
2-- NHCH2 CH2 -(1H-1,2,4-triazol-1-yl),
25 --NH--CH2 CH2 -(1-imidazolyl),
26 --NH--CH2 CH2 -(2H-tetrazol-2-yl),
27 --NH--CH2 CH2 -(1H-tetrazol-1-yl),
28 --N(CH3)CH2 CH2 -(4-imidazolyl),
29 --N(CH3)CH2 CH2 N(CH3)Ac,
30 --N(CH3)CH2 CH2 N(CH3)C(O)NHCH3,
31 --N(CH3)CH2 CH2 N(CH3)SO2 CH3,
32 --NHCH2 CH2 -(1,1-dioxo-4-thiamorpholinyl),
33 4-dimethylaminobenzylamino,
34 3-dimethylaminoanilino,
35 --N(CH3)CH2 CH2 -(1,1-dioxo-4-thia-morpholinyl),
36 4-dimethylaminoanilino,
37 --NHCH2 CH2 -(1-benzyl-1H-imidazol-2-yl),
38 --N(CH3)CH2 CH2 (2-pyridyl),
39 --NHCH2 CH2 (4-benzyloxycarbonyl-1-piperazinyl),
40 1,2-diethylpyrazolidin-4-yl amino,
41 2-(1-S-pyrrolidinylmethyl)-1-pyrrolidinyl,
42 --NHCH2 CH2 (4-hydroxy-1-piperidinyl),
43 --NHCH2 CH2 (1-homopiperidinyl),
44 --N(CH3)CH2 CH2 (1-homopiperidinyl),
45 --NHCH2 CH2 (3-hydroxy-1-piperidinyl),
46 --N(CH3)CH2 CH2 (3-hydroxy-1-piperidinyl),
47 --N(CH3)CH2 CH2 N(CH3)CH2 Ph,
48 --N(CH3)CH2 CH2 (4-benzyloxy-1-piperidinyl),
49 --N(n-Pr)2,
50 --N(Et)2,
51 --N(CH3)CH2 CH2 (4-hydroxy-1-piperidinyl),
52 --N(CH3)CH2 CH2 (4-oxo-1-piperidinyl),
53 --NHCH2 CH2 (3-hydroxy-1-pyrrolidinyl),
54 --N(Et)CH2 CH2 (1-piperidinyl),
55 --N(CH2 Ph)CH2 CH2 (1-piperidinyl),
56 4-fluoroanilino-,
57 3-chloroanilino-,
583-methoxyanilino,
59 --N(CH2 Ph)CH2 CH2 N(CH3)2,
60 --N(CH3)CH2 CH2 (3-hydroxy-1-pyrrolidinyl),
61 --N(3-picolyl)CH2 CH2 (1-piperidinyl),
62 --NHCH(CH3)CH2 CH2 CH2 N(Et)2,
63 --NHCH2 CH2 (2-S-hydroxymethyl-1-pyrrolidinyl,
64 --N(CH3)CH2 CH2 (4t-butoxycarbonyl-1-piperazinyl),
65 --N[CH2 CH2 N(CH3)2]2,
66 --N [CH2 CH2 N(Et)2]2,
67 --N(CH3)CH2 CH2 N(CH3)(3-picolyl),
68 3,5-dimethyl-1-piperazinyl,
69 --N(CH3)CH2 CH2 N(O)(CH3)CH2 Ph,
70 --N(CH3)CH2 CH2 N(CH3)(4-picolyl),
71 2-S-(N-benzyl-N-methylaminomethyl)-1-pyrrolidinyl,
72 --N(CH3)CH2 CH2 N(CH3)(2-picolyl),
73 --N(CH3)CH2 CH2 (1-piperazinyl),
74 1-homopiperazinyl,
75 --N(CH3)CH2 CH2 N(CH3)CH2 CH2 Ph,
76 2-(1-R-pyrrolidinylmethyl)-1-pyrrolidinyl,
77 4-benzyl-1-homopiperazinyl,
78 --N(CH3)CH2 --[CH(OH)]4 CH2 OH,
79 --N(CH3)CH2 --[CH(OAc)]4 CH2 OAc,
80 --N(CH3)CH2 CH2 N(CH3)(1-naphthalenylmethyl),
81 --N(CH3)CH2 CH2 N(CH3)(2-naphthalenylmethyl),
82 --N(CH3)CH2 CH2 N(CH3)CH(CH3)Ph,
83 --N(CH3)CH2 CH2 N(CH2 Ph )2,
84 1-ethyl-3-piperidinylamino,
85 --N(CH3)CH2 CH2 N(CH3)(2-furfuryl),
86 --N(CH3)CH2 CH2 CH2 CO2 H,
87 --N(CH3)CH2 CH2 CH2 C(O)NHSO2 Ph,
88 --N(CH3)CH2 CH2 N(CH3)CH2 CH═CH2,
89 --N(CH3)CH2 CH2 CH2 N(CH3)CH2 Ph,
90 --N(CH3)--(CH2)6 --N(CH3)CH2 Ph,
91 --N(CH3)CH2 CH2 OH,
9-- N(CH3)CH2 CH2 OC(O)N(CH3)2,
93 --N(CH3)CH2 CH2 N(CH3)CH2 CO2 -t-Bu,
94 --N(CH3)(1-ethyl-3-piperidinyl),
95 --N(CH3)CH2 CH2 N(CH3)(tetrahydro-2H-pyran-2-yl-methyl),
96 2,2,6,6-tetramethylpiperidin-4-ylamino,
97 --N(CH3)(4-carboxyphenyl),
98 --N(CH3)(4-benzenesulfonylaminocarbonyl,-phenyl
99 --N(CH3)CH2 CH2 N(CH3)(4-cyanobenzyl),
100 --N(CH3)CH2 CH2 N(CH3)(4-methylbenzyl),
101 --N(CH3)CH2 CH2 N(CH3)(3-cyanobenzyl),
102 --N(CH3)CH2 CH2 N(CH3)(4-trifluoro-methylbenzyl,
103 --N(CH3)CH2 CH2 N(CH3)(3-trifluoromethyl-benzyl),
104 --N(CH3)CH2 CH2 (CH3)(4-fluorobenzyl),
105 --NHCH(CH3)PH(O)OH,
106 --N(CH3)CH2 CH2 N(H3)(cyclopropylmethyl),
107 --N(CH3)CH2 CH(Ph)N(CH3)2,
108 --N(CH3)2,
109 --N(CH3)CH2 Ph,
110 --N(CH3)(1-benzyl-3-piperidinyl),
111 --NH-O-CH2 Ph,
112 --N(3-picolyl)CH2 CH2 N(CH3)CH2 PH,
113 --N(CH3)CH2 CH2 N(CH3)(4-methoxybenzyl),
114 --N(4-picolyl)CH2 CH2 N(CH3)CH2 Ph,
115 --N(2-picolyl)CH2 CH2 N(CH3)CH2 Ph,
116 --N(CH3)CH2 CH2 N(CH3)(2,4-dimethylbenzyl),
117 --N(CH3)CH2 CH2 (2,6-dimethyl-4-morpholinyl),
118 --NH2,
119 --NHCH3,
120 4-morpholinyl,
121 cis-2,6-dimethyl-4-morpholinyl,
122 --NH--CH2 CH2 CH2 CH3,
123 --N(CH3)CH2 CH2 N(CH3)C(═N--CN)NHPh,
124 --N(CH3)CH2 CH2 N(CH3)(3-fluorobenzyl),
125 --N(CH3)CH2 CH2 N(CH3)(2-chlorobenzyl),
12-- N(CH3)CH2 CH2 N(CH3)(3-methoxybenzyl),
127 --N(CH3)CH2 CH2 N(CH3)(3,5-dimethoxybenzyl),
128 3,4-dihydro-6,7-dimethoxy-2-(1H)iso-quinolinyl,
129 --N(CH3)(1-benzyl-4-piperidinyl),
130 --N(CH3)CH2 CH2 N(CH3)(2-adamantyl),
131 --N(CH3)(4-piperidinyl),
132 5-Methyl-2,5-diazabicyclo[2.2.1 ]hept-2-yl,
133 --N(CH3)CH2 CO2 H,
134 --N(CH3)CH2 CH2 CH2 N(CH3)CH2 CH3,
135 --N(CH3)(1-methyl-4-piperidinyl),
136 --N(CH3)(1-propyl-4-piperidinyl),
137 --N(CH3)(1-ethyl-4-piperidinyl),
138 --N(CH3)CH2 CH(CH3)N(CH3)CH2 Ph,
139 --N(CH3)CH2 CH(CH3)N(CH3)2,
140 --N(CH3)CH2 CH2 NH(2-adamantyl),
141 --N(CH3)CH2 CH2 N(CH3)(6,6-dimethylbicyclo-[3.1 .1]hept-2-yl,
142 --NH(t-Bu),
143 --N(CH3)CH2 CH2 N(CH3)(1-cyclohexen-1-yl),
144 --N(CH3)CH2 CH2 NHC(CH3)2 CH═CH2,
145 2-S-carboxamido-1-pyrrolidinyl,
146 2-hydroxymethyl-1-piperidinyl,
147 3-dimethylamino-1-pyrrolidinyl,
148 --N(CH3)CH2 CH2 N(CH3)(cyclohexylmethyl),
149 --N(CH3)CH2 CH2 N(CH2 CH=CH2)C(CH3)2 CH═CH2,
150 --N(CH3)CH2 CH2 N(CH3)(4-ethylcyclohexyl),
151 --N(CH3)CH2 CH2 N(CH3)(2-ethylcyclohexyl),
152 --N(CH3)CH2 CH2 N(CH3)(4-methylcyclohexyl),
153 --N(CH3)CH2 CH2 N(CH3)(cyclohexyl),
154 --N(CH3)CH2 CH2 N(CH3)CH2 C(O)N(CH3)2,
155 3-dimethylamino-1-azetidinyl,
156 1-diphenylmethyl-3-azetidinyl,
157 --N(CH)CH2 CH2 N(CH3)(cyclohexylmethyl), or
158 --NH CH2 CH2 N(Et)CH2 CH2 OCH3.
10. A compound of formula (I): ##STR50## or a pharmaceutically acceptable salt thereof wherein: R is C1-6 alkyl;
R1 is C1-6 alkyl or C1-6 alkoxy-C1-6 alkyl;
M is
(2) ethyl, propyl, butyl, pentyl or hexyl,
(3) hydroxy C1-6 alkyl,
(4) halo C1-6 alkyl,
(5) C2-6 alkenyl, or
(6) C1-6 alkoxy-C1-6 alkyl;
Ra and rb are each individually
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(4) carboxy,
(5) C1-6 alkoxy,
(6) phenyl,
(7) C1-6 alkylcarbonyl,
(8) di-(C1-6 alkyl)amino,
(9) hydroxy;
R2 is
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(4) C1-6 alkoxy,
(5) phenyl,
(6) C1-6 alkylcarbonyl,
(7) amino C2-3 alkyloxy carbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(8) aminoC2-3 alkylamino carbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(9) hydroxy,
(10) aminocarbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(11) hydroxymethyl,
(12) aminocarbonyloxy C1-3 alkyl, wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(13) cyano,
(14) morpholinocarbonylphenyl,
(15) amino wherein the amino is optionally mono- or di-substituted with C1-6 alkyl, or
(16) morpholinocarbonyl;
R3 is
(1) C1-6 alkyl,
(2) halo,
(3) C1-6 alkoxy,
(4) phenyl,
(5) C1-6 alkylcarbonyl,
(6) aminoC2-3 alkyloxy carbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(7) aminoC2-3 alkylamino carbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(8) hydroxy,
(9) aminocarbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(10) hydroxymethyl,
(11) aminocarbonyloxy C1-3 alkyl, wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(12) cyano,
(13) morpholinocarbonylphenyl,
(14) amino wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(15) morpholinocarbonyl, with the proviso that R2 and R3 may be joined together to form a methylenedioxy group or a furan ring;
R4 is (a) ##STR51## or ##STR52## where Rx is carboxy C1-6 alkyl, benzyloxycarbonylC1-3 alkyl, or t-butoxycarbonyl-C1-3 alkyl,
wherein
Q is a covalent bond or ##STR53## wherein R5 and R6 are each individually C1-3 alkyl or hydrogen,
Y is ##STR54## or a covalent bond; R12 is hydrogen or C1-3 alkyl;
R7 is
(a) ethyl, propyl, butyl, pentyl or hexyl,
(b) C1-6 alkyloxy C2-3 alkyl,
(c) hydroxy C2-6 alkyl,
(d) polyhydroxyC2-6 alkyl,
(e) carboxamido C1-6 alkyl,
(f) C1-6 alkanoyl,
(g) substituted phenyl or phenyl C1-6 alkyl, wherein the substituents are X1 and X2 as defined immediately below,
(h) C2-6 alkenyl,
(i) C6-10 cycloalkenyl,
(j) heteroaryl C1-6 alkyl wherein the hetero aryl is selected from pyridinyl, imidazolyl, triazolyl, benzylimidazolyl, and furyl,
(k) carboxy C1-6 alkyl,
(l) carbo C1-6 alkoxy C1-3 alkyl,
(m) phenylsulfonyl,
(n) C1-6 alkylsulfonyl,
(o) benzyloxy,
(p) morpholinyl C1-3 alkylsulfonyl,
(q) tetrahydropyranyl,
(r) aminoC1-3 alkylsulfonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(s) aminocarbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(t) aminocarbonyloxyC2-6 alkyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(u) azabicyclo of 7 to 12 atoms,
(v) di C1-3 alkylamino C2-6 alkyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(w) bicycloalkyl of 7 to 12 atoms,
(x) C3-10 cycloalkyl optionally substituted with C1-6 alkyl,
(y) pyrazolidinyl,
(z) substituted piperidinyl or pyrrolidinyl wherein the substituent is hydrogen, C1-3 alkyl, hydroxy C1-3 alkylbenzyl, carboxamido or amino wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(aa) substituted pyrrolidinyl wherein the substituent is carboxamido or amino wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(bb) pyrimidinyl,
(cc) phosphonoC1-6 alkyl, or
(dd) α-C1-3 alkyl benzyl or mono- or di-substituted benzyl or mono- or di-substituted pyridylmethyl, wherein the substituents are X1 and X2,
R8 is
(a) C1-6 alkyl,
(b) C1-6 alkyloxy C2-3 alkyl,
(c) hydroxy C2-6 alkyl,
(d) polyhydroxyC2-6 alkyl,
(e) carboxamido C1-6 alkyl,
(f) C1-6 alkanoyl,
(g) substituted phenyl or phenyl C1-6 alkyl, wherein the substituents are X1 and X2 as defined immediately below,
(h) C2-6 alkenyl,
(i) C6-10 cycloalkenyl,
(j) heteroaryl C1-6 alkyl wherein the hetero aryl is selected from pyridinyl, imidazolyl, triazolyl, benzylimidazolyl, and furyl,
(k) carboxy C1-6 alkyl,
(l) carbo C1-6 alkoxy C1-3 alkyl,
(m) phenylsulfonyl,
(n) C1-6 alkylsulfonyl,
(o) benzyloxy,
(p) morpholinyl C1-3 alkylsulfonyl,
(q) tetrahydropyranyl,
(r) aminoC1-3 alkylsulfonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(s) aminocarbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(t) aminocarbonyloxyC2-6 alkyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(u) azabicyclo of 7 to 12 atoms,
(v) di C1-3 alkylamino C2-6 alkyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(w) bicycloalkyl of 7 to 12 atoms,
(x) C3-10 cycloalkyl optionally substituted with C1-6 alkyl,
(y) pyrazolidinyl,
(z) substituted piperidinyl or pyrrolidinyl wherein the substituent is hydrogen, C1-3 alkyl, hydroxy C1-3 alkylbenzyl, carboxamido or amino wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(aa) substituted pyrrolidinyl wherein the substituent is carboxamido or amino wherein the amino is optionally mono- or di-substituted with C1-6 alkyl,
(bb) pyrimidinyl,
(cc) phosphonoC1-6 alkyl, or
(dd) α-C1-3 alkyl benzyl or mono- or di-substituted benzyl or mono- or di-substituted pyridylmethyl, wherein the substituents are X1 and X2,
wherein
X1 is
(1) hydrogen,
(2) halo,
(3) C1-6 alkyl,
(4) halo-C1-6 alkyl,
(5) C2-6 alkenyl,
(6) hydroxy-C1-6 alkyl,
(7) C1-6 alkylcarbonyl,
(8) C1-6 alkylcarbonylamino,
(9) CN,
(10) CF3,
(11) CH3 O,
(12) amino wherein the amino is optionally mono or di substituted with C1-6 alkyl,
(13) carboxy, or
(14) phenylsulfonylaminocarbonyl;
X2 is hydrogen, halo or C1-6 alkyl;
n is 1, 2, 3, 4 or 5;
R9 is selected from hydrogen, C1-4 alkyl, and C1-3 alkoxyC2-3 alkyl; or phenyl, phenyl C1-3 alkyl, pyridyl, and pyridyl C1-3 alkyl;
R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl, or are together O═; or
wherein
R7 and R8 are joined together with the nitrogen to which they are attached to form mono- or di-substituted ring selected from
(1) piperidinyl or homopiperdinyl,
(2) piperazinyl,
(3) morpholinyl, thiomorpholinyl or 1,1-dioxo-4-thio-morpholinyl,
(4) pyrroylidinyl,
(5) pyrryl,
(6) imidazolyl,
(7) triazolyl,
(8) saturated azabicyclo of 7 to 12 atoms,
(9) azaspiro having 3 to 9 carbon atoms, said ring being saturated,
(10) tetrazolyl,
(11) pyrazolidinyl,
(12) azetidinyl, or
(13) diazabicyclo ring of 7-12 atoms,
wherein the substituents are each selected from the group consisting of hydrogen and C1-3 alkyl, benzyloxycarbonyl, phenyl C1-3 alkyl amino carbonyl, pyrrolidinylmethyl, hydroxy C1-3 alkyl, C1-6 alkyloxy, C1-4 alkyloxy carbonyl, aminocarbonyl wherein the amino is optionally mono- or di-substituted with C1-6 alkyl, and oxo; or
--N(R7)R8 is
--NH--(CH2)3 --C(H)(NH2)--C(O)OH, or
NH2 --(CH2)3 --C(H)(NH)--C(O)OH;
R8 R9 are joined together to form a mono- or di-substituted saturated monocyclic ring of 6 to 7 atoms and having two hetero atoms which are the nitrogens to which R8 are attached; or R9 and R10 are joined together to form a mono- or di-substituted monocyclic saturated ring of 5 to 7 atoms and having one hetero atom which is the nitrogen to which R9 is attached; or wherein R9 and R12 are joined together to form a mono- or di-substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R9 is attached; or
wherein R10 and R12 are joined together with the carbons to which they are attached to form a mono- or di-substituted saturated monocyclic ring of 5, 6, or 7 carbon atoms; or wherein R8 and R11 are joined together to form a mono- or disubstituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R8 is attached, and the substituents are independently selected from hydrogen and C1-3 alkyl.
2. A compound of formula I according to claim 1
wherein
Q is a covalent bond,
Y is ##STR42## and R4 is ##STR43##
3. A compound according to claim 2 wherein
R is C1-6 alkyl;
R1 is C1-6 alkyl or C1-6 alkoxy-C1-6 alkyl;
M is
(1) hydrogen,
(2) C1-6 alkyl,
(3) hydroxy C1-6 alkyl,
(4) halo C1-6 alkyl,
(5) C2-6 alkenyl, or
(6) C1-6 alkoxy-C1-6 alkyl;
Ra is
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(4) carboxy,
(5) C1-6 alkoxy,
(6) phenyl,
(7) C1-6 alkylcarbonyl,
(8) amino wherein the amino may be optionally mono or di substituted with C1-6 alkyl;
rb is hydrogen or C1-3 alkyl,
R2 and R3 are each independently
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(5) C1-6 alkoxy,
(6) phenyl,
(7) C1-6 alkylcarbonyl,
(8) di-(C1-6 alkyl)amino, or with the proviso that when rb is hydrogen, R2 and R3 may be joined together to form a methylenedioxy group or a furan ring;
R4 is ##STR44## wherein Q is a covalent bond
Y is ##STR45## R12 is hydrogen or C1-3 alkyl; R7 and R8 are each individually
(a) hydrogen,
(b) C1-6 alkyl,
(c) C1-6 alkyloxy C2-3 alkyl,
(d) hydroxy C2-6 alkyl,
(e) carboxamido C1-6 alkyl,
(f) C1-6 alkanoyl,
(g) phenyl or phenyl C1-6 alkyl,
(h) C2-6 alkenyl,
(i) C6-10 cycloalkenyl,
(j) heteroaryl C1-6 alkyl wherein the heteroaryl selected form pyridinyl, imidazolyl, triazolyl, benzylimidazolyl, and furyl,
(k) carboxy C1-6 alkyl,
(l) C1-6 alkylsulfonyl,
(m) benzyloxy,
(n) morpholinyl C1-3 alkylsulfonyl,
(o) aminoC1-3 alkylsulfonyl wherein the amino is optionally substituted with C1-6 alkyl,
(p) aminocarbonyl wherein the amino is optionally substituted with C1-6 alkyl,
(q) aminocarbonyloxyC2-6 alkyl wherein the amino is optionally substituted with C1-6 alkyl,
(r) amino C2-6 alkyl wherein the amino is optionally substituted with C1-6 alkyl,
(s) pyrazolidinyl,
(t) piperidinyl,
(u) pyrrolidinyl
(v) pyrimidinyl,
(w) C3-7 cycloalkyl,
(x) α-C1-3 alkyl benzyl or mono or di substituted benzyl or mono or di substituted pyridylmethyl, wherein the substitutents are X1 and X2,
wherein
X1 is
(1) hydrogen,
(2) halo,
(3) C1-6 alkyl,
(4) halo-C1-6 alkyl,
(5) C2-6 alkenyl,
(6) hydroxy-C1-6 alkyl,
(7) C1-6 alkylcarbonyl,
(8) C1-6 alkylcarbonylamino;
(9) amino wherein the amino is optionally substituted with C1-6 alkyl; or
(10) carboxy,
X2 is hydrogen, halo or C1-6 alkyl;
n is 1, 2, 3 or 4;
R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl; or
wherein R7 and R8 are joined together with the nitrogen to which they are attached to form mono or di substituted ring of selected from
(1) piperidinyl,
(2) piperazinyl,
(3) morpholinyl,
(4) pyrroylidinyl,
(5) pyrryl,
(6) imidazolyl,
(7) triazolyl,
(8) tetrazolyl,
(9) pyrazolidinyl, or
(10) azetidinyl,
wherein the substituents are each selected from the group consisting of hydrogen and C1-3 alkyl, benzyloxycarbonyl, phenyl C1-3 alkyl amino carbonyl, pyrrolidinyl, methyl, hydroxy C1-3 alkyl, C1-6 alkyloxy, C1-4 alkyloxy carbonyl, and oxo; or
wherein R10 and R12 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 carbon atoms; or
wherein R8 and R11 are joined together with the nitrogen to which R8 is attached to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R8 is attached, and the substituents are independently selected from Hydrogen and C1-3 alkyl.
4. A compound according to claim 3
wherein
R is C1-3 alkyl;
R1 is C1-3 alkyl;
M is
(a) C1-6 alkyl, or
(b) C2-6 alkenyl;
R2 is
(a) hydrogen
(b) C1-6 alkyl, or C1-6 alkoxy, and
R3 is hydrogen, or
R2 and R3 are joined together to form a methylenedioxy group or a furan ring;
R7 and R8 are each independently selected from
(a) hydrogen,
(b) C1-3 alkyl,
(c) C1-3 alkoxy C2-3 alkyl,
(d) substituted benzyl wherein the substituents are X1 and X2
wherein X1 is hydrogen and X2 is
(1) hydrogen,
(2) halo, or
(3) C1-3 alkyl;
n is 1, 2 or 3, and
R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl; or
R7 and R8 are joined together to form a substituted ring selected from
(a) piperidinyl,
(b) piperazinyl, and
(c) morpholinyl; or
wherein R10 and R12 are joined together with the carbons to which they are attached to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 carbon atoms; or
wherein R8 and R11 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R8 is attached, and the substituents are independently selected from Hydrogen and C1-3 alkyl.
5. A compound according to claim 4 wherein
R is methyl or ethyl;
R1 is methyl or ethyl;
M is
(a) C1-4 alkyl, or
(b) C2-3 alkenyl;
R2 is
(a) hydrogen,
(b) C1-3 alkyl, or C1-3 alkoxy, and
R3 is hydrogen, or
R2 and R3 are joined together to form a methylenedioxy group or a furan ring;
n is 1 or 2;
R10 is selected from
(a) C1-3 alkyl,
(b) C1-3 alkoxy C2-3 alkyl,
(c) hydrogen,
R7 and R8 are independently selected from
(a) hydrogen,
(b) cyclopropyl,
(c) C1-3 alkyl,
(d) C1-3 alkoxy C2-3 alkyl,
or
R7 and R8 are joined together with the nitrogen to which they are attached to form a substituted ring selected from
(a) piperidinyl, and
(b) morpholinyl; or
wherein R10 and R12 are joined together with the carbons to which they are attached to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 carbon atoms; or
wherein R8 and R11 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R8 is attached, and the substituents are independently selected from Hydrogen and C1-3 alkyl.
6. A compound according to claim 1 wherein
Q is a covalent bond,
R4 is ##STR46## and Y is ##STR47##
7. A compound according to claim 6 wherein
R is C1-6 alkyl;
R1 is C1-6 alkyl or C 1-6 alkoxy-C1-6 alkyl;
M is
(1) hydrogen,
(2) C1-6 alkyl,
(3) hydroxy C1-6 alkyl,
(4) halo C1-6 alkyl,
(5) C2-6 alkenyl, or
(6) C1-6 alkoxy-C1-6 alkyl;
Ra is
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(5) C1-6 alkoxy,
(6) phenyl,
(7) C1-6 alkylcarbonyl,
(8) di-(C1-6 alkyl)amino;
rb is hydrogen or C1-6 alkyl,
R2 and R3 are each independently
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(5) C1-6 alkoxy,
(6) phenyl,
(7) C1-6 alkylcarbonyl,
(8) di-(C1-6 alkyl)amino, or
R2 and R3 may be joined together to form a methylenedioxy group or a furan ring;
R4 is ##STR48## wherein Q is a covalent bond,
Y is ##STR49## R12 is hydrogen or C1-3 alkyl; R7 and R8 are each individually
(a) hydrogen,
(b) C1-6 alkyl,
(c) C1-6 alkyloxy C2-3 alkyl,
(d) hydroxy C2-6 alkyl,
(e) carboxamido C1-6 alkyl,
(f) C1-6 alkanoyl,
(g) phenyl or phenyl C1-6 alkyl,
(h) C2-6 alkenyl,
(i) C6-10 cycloalkenyl,
(j) heteroaryl C1-6 alkyl wherein the heteroaryl selected from pyridinyl, imidazolyl, triazolyl, benzylimidazolyl, and furyl,
(k) carboxy C1-6 alkyl or carboC1-6 alkoxyC1-6 alkyl,
(l) C1-6 alkylsulfonyl,
(m) benzyloxy,
(n) morpholinyl C1-3 alkylsulfonyl,
(o) aminoC1-3 alkylsulfonyl wherein the amino may be optionally substituted with C1-6 alkyl,
(p) aminocarbonyl wherein the amino may be optionally substituted with C1-6 alkyl,
(q) aminocarbonyloxyC1-6 alkyl wherein the amino may be optionally substituted with C1-6 alkyl,
(r) amino C1-6 alkyl wherein the amino may be optionally substituted with C1-6 alkyl,
(s) pyrazolidinyl,
(t) piperidinyl,
(u) pyrrolidinyl
(v) pyrimidinyl,
(w) C3-7 cycloalkyl,
(x) α-C1-3 alkyl benzyl or mono or di substituted benzyl or mono or di substituted pyridylmethyl, wherein the substitutents are X1 and X2,
wherein
X1 is
(1) hydrogen,
(2) halo,
(3) C1-6 alkyl,
(4) halo-C1-6 alkyl,
(5) C2-6 alkenyl,
(6) hydroxy-C1-6 alkyl,
(7) C1-6 alkylcarbonyl,
(8) C1-6 alkylcarbonylamino;
(9) di-C1-3 alkylamino; or
(10) carboxy,
X2 is hydrogen, halo or C1-6 alkyl;
n is 1, 2, 3 or 4;
R9 is selected from hydrogen, C1-4 alkyl, and C1-3 alkoxyC1-3 alkyl;
R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl; or
wherein
R7 and R8 are joined together with the nitrogen to which they are attached to form mono or di substituted ring selected from
(1) piperidinyl,
(2) piperazinyl,
(3) morpholinyl,
(4) pyrroylidinyl,
(5) pyrryl,
(6) imidazolyl,
(7) triazolyl,
(8) tetrayolyl,
(9) pyrazolidinyl, or
(10) azetidinyl,
wherein the substituents are each selected from the group consisting of hydrogen and C1-3 alkyl, benzyloxycarbonyl, phenyl C1-3 alkyl amino carbonyl, pyrrolidinyl, methyl, hydroxy C1-3 alkyl, C1-6 alkyloxy, C1-4 alkyloxy carbonyl, and oxo; or R8 and R9 are joined together to form a mono or di substituted saturated monocyclic ring of 6 to 7 atoms and having two hetero atoms which are the nitrogens to which R8 and R9 are attached; said rings selected from piperazinyl and homopiperazinyl; or R9 and R10 are joined together to fonn a mono or di substituted monocyclic saturated ring of 5 to 7 atoms and having one hetero atom which is the nitrogen to which R9 is attached; or wherein R9 and R12 are joined together with the nitrogen to which R9 is attached to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R9 is attached; or
wherein R10 and R12 are joined together with the carbons to which they are attached to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 carbon atoms; or
wherein R8 and R11 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R8 is attached, and the substituents are independently selected from hydrogen and C1-3 alkyl.
8. A compound according to claim 7 wherein
R is C1-3 alkyl;
R1 is C1-3 alkyl;
M is
(a) C 1-6 alkyl, or
(b) C2-6 alkenyl;
R2 is
(a) hydrogen
(b) C1-6 alkyl, or C1-6 alkoxy, and
R3 is hydrogen, or
R2 and R3 are joined together to form a methylenedioxy group or a furan ring;
R7 and R8 are each independently selected from
(a) hydrogen,
(b) C1-3 alkyl,
(c) C1-3 alkoxy C2-3 alkyl,
(d) C3-7 cycloalkyl,
(e) hydroxyC2-3 alkyl,
(f) carboC1-4 alkoxymethyl,
(g) substituted benzyl wherein the substituents are X1 and X2
wherein
X1 is hydrogen and X2 is
(1) hydrogen,
(2) halo, or
(3) C1-3 alkyl;
n is 1, 2 or 3, and
R9, R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl; or
R7 and R8 are joined together with the nitrogen to which they are attached to form a substituted ring selected from
(a) piperidinyl,
(b) piperazinyl, and
(c) morpholinyl;
or
R8 and R9 are joined together to form a mono or di substituted saturated monocyclic ring of 6 to 7 atoms and having two hetero atoms which are the nitrogens to which R8 and R9 are attached.
9. A compound according to claim 8 wherein
R is methyl or ethyl;
R1 is methyl or ethyl;
M is
(a) C1-4 alkyl, or
(b) C2-3 alkenyl;
R2 is
(a) hydrogen,
(b) C1-3 alkyl, or C1-3 alkoxy, and
R3 is hydrogen, or
R2 and R3 are joined together to form a methylenedioxy group or a furan ring;
n is 1 or 2;
R9 and R10 are each independently selected from
(a) hydrogen,
(b) C1-3 alkyl,
(c) C1-3 alkoxy C1-3 alkyl,
R7 and R8 are each independently selected from
(a) hydrogen,
(b) C1-3 alkyl,
(c) cyclopropyl,
(d) C1-3 alkoxy C1-3 alkyl,
(e) hydroxyethyl,
(f) carboethoxymethyl,
or
R7 and R8 are joined together with the nitrogen to which they are attached to form a mono or di substituted saturated monocyclic ring which is piperidinyl or morpholinyl, said ring optionally substituted with hydrogen or methyl; or R8 and R9 are joined together to form a mono or di substituted saturated monocyclic ring which is piperazinyl.
12. A compound according to claim 1 of the formula ##STR56## wherein A is
-- CH2 CH2 N(CH3)2,
2 --CH2 CH2 CH2 N(CH3)2,
3 --CH2 CH2 N(Et)2,
4 --CH2 CH2 -(4-morpholinyl),
5 --CH(CH3)CH2 N(CH3)2,
6 --CH2 -C(CH3)2 N(CH3)2, or
8 --CH2 CH2 N(CH3)CH2 Ph.
20. A compound according to claim 1 of the formula ##STR63## where n, R2, R6, and A are:
______________________________________
No. R2 R6 A
______________________________________
1 CH3
CH3 --OCH2 CH2 N(CH3)2,
2 CH3
CH3 --OCH2 CH2 N(Et)2,
3 CH3
CH3 --OCH2 CH2 N(i-Pr)2,
4 CH3
CH3 --N(CH3)CH2 CH2 N(CH3)2,
2
5 CH3
CH3 --N(CH3 CH2 CH2 N(Et)2,
6 CH3
CH3 --N(Et)CH2 CH2 N(CH3)2, or
7 H OH --N(CH3)CH2 CH2 N(CH3)2.
______________________________________
24. A compound according to claim 1 which is
(a) [S-(R*,S*)]-2-[4-[[((2-Dimethylamino)ethyl)methylamino]carbonyl]phenoxy]-3 ,3-diethyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(b) [S-(R*,S*)]-2-[4-[[(4-Methyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl- N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidine-carboxamide,
(c) [S-(R*,S*)]-2-[4-[[(4-Methyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl- N-[1-3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(d) [S-(R*,S*)]-2-[4-[[(4-Cyclopropyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-die thyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(e) [S-(R*,S*)]-2-[4-[[(4-Cyclopropyl)piperazin-1-yl]carbonyl]phenoxy]3,3-diet hyl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide,
(f) [S-(R*,S*)]-2-[4-[(piperazin-1-yl)carbonyl]phenoxy]-3,3-diethyl-N-[1-(4-me thylphenyl)butyl]-4-oxo-1-azetidine-carboxamide, or
(g) [S-(R*,S*)]-2-[4-[(piperazin-1-yl)carbonyl]phenoxy]-3,3-diethyl-N-[1-(3,4- methylenedioxyphenyl)butyl ]-4-oxo-1-azetidinecarboxamide.
25. A pharamaceutical composition for the inhibition of human leukocyte elastase which comprises a nontoxic therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
26. A method of treatment for the inhibition of human leukocyte elastase which comprises the administration to a subject in need of such inhibition a nontoxic therapeutically effective amount of a compound of claim 1.
28. A compound according to claim 10 which is
(a) [S-(R*,S*)]-2-[4-[(4-morpholinyl)carbonyl]phenoxy]-3,3-diethyl-N-[1-(4-met hylphenyl)butyl]-4-oxo-1-azetidinecarboxamide, or
(b) [S-(R*,S*)]-2-[4-[(4-morpholinyl)carbonyl]phenoxy]3,3-diethyl-N-[1-(3,4-me thylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide.
29. A compound according to claim 10 wherein
Ra is
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(5) C1-6 alkoxy,
(6) phenyl,
(7) C1-6 alkylcarbonyl,
(8) di-(C1-6 alkyl)amino;
rb is hydrogen or C1-6 alkyl,
R2 is
(1) hydrogen,
(2) C1-6 alkyl,
(3) halo,
(5) C1-6 alkoxy,
(6) phenyl,
(7) C1-6 alkylcarbonyl, or
(8) di-(C1-6 alkyl)amino,
R3 is
(1) C1-6 alkyl,
(2) halo,
(4) C1-6 alkoxy,
(5) phenyl,
(6)C1-6 alkylcarbonyl,
(7) di-(C1-6 alkyl)amino, or
R2 and R3 may be joined together to form a methylenedioxy group or a furan ring;
R4 is ##STR65## R7 is (b) ethyl, propyl, butyl, pentyl or hexyl,
(c) cyclopropyl,
(d) C1-3 alkoxy C1-3 alkyl,
(e) hydroxyethyl,
(f) carboethoxymethyl,
R8 is
(b) C1-3 alkyl,
(c) cyclopropyl,
(d) C1-3 alkoxy C1-3 alkyl,
(e) hydroxyethyl,
(f) carboethoxymethyl, or
R7 and R8 are joined together with the nitrogen to which they are attached to form mono or di substituted monocyclic ring which is piperidinyl or morpholinyl, said ring optionally substituted with hydrogen or methyl.
30. A compound according to claim 10 wherein
R is C1-3 alkyl;
R1 is C1-3 alkyl;
M is
(1) ethyl, propyl, butyl, pentyl or hexyl, or
(2) C2-6 alkenyl;
R2 is
(a) hydrogen,
(b) C1-6 alkyl or C1-6 alkoxy, or
R3 is hydrogen, or
R2 and R3 are joined together to form a methylenedioxy group or a furan ring;
R9, R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy-C1-3 alkyl;
R7 and R8 are joined together with the nitrogen to which they are attached to form mono or di substituted ring selected from
(1) piperidinyl,
(2) piperazinyl,
(3) morpholinyl,
(4) pyrroylidinyl,
(5) pyrryl,
(6) imidazolyl,
(7) triazolyl,
(8) tetrayolyl,
(9) pyrazolidinyl, or
(10) azetidinyl,
wherein the substituents are each selected from the group consisting of hydrogen and C1-3 alkyl, benzyloxycarbonyl, phenyl C1-3 alkyl amino carbonyl, pyrolidinyl, methyl, hydroxy C1-3 alkyl, C1-6 alkyloxy, C1-4 alkyloxy carbonyl, and oxo.
31. A compound according to claim 30 wherein
R is methyl or ethyl;
R1 is methyl or ethyl;
M is
(1) ethyl, propyl or butyl, or
(2) C2-3 alkenyl;
R2 is
(a) hydrogen
(b) C1-3 alkyl or C1-3 alkoxy.

This is a continuation of application Ser. No. 07/991,838 filed on Dec. 17, 1992, abandoned.

BACKGROUND OF THE INVENTION

We have found that a group of new substituted azetidinones are potent elastase inhibitors and therefore are useful anti-inflammatory and antidegenerative agents.

Proteases from granulocytes and macrophages have been reported to be responsible for the chronic tissue destruction mechanisms associated with inflammation, including rheumatoid arthritis and emphysema. Accordingly, specific and selective inhibitors of these proteases are candidates for potent anti-inflammatory agents useful in the treatment of inflammatory conditions resulting in connective tissue destruction, e.g. rheumatoid arthritis, emphysema, bronchial inflammation, chronic bronchitis, glomerulonephritis, osteoarthritis, spondylitis, lupus, psoriasis, atherosclerosis, sepsis, septicemia, shock, myocardial infarction, reperfusion injury, periodontitis, cystic fibrosis and acute respiratory distress syndrome.

The role of proteases from granulocytes, leukocytes or macrophages are related to a rapid series of events which occurs during the progression of an inflammatory condition:

(1) There is a rapid production of prostaglandins (PG) and related compounds synthesized from arachidonic acid. This PG synthesis has been shown to be inhibited by aspirin-related nonsteroidal anti-inflammatory agents including indomethacin and phenylbutazone. There is some evidence that protease inhibitors prevent PG production;

(2) There is also a change in vascular permeability which causes a leakage of fluid into the inflamed site and the resulting edema is generally used as a marker for measuring the degree of inflammation. This process has been found to be induced by the proteolytic or peptide cleaving activity of proteases, especially those contained in the granulocyte, and thereby can be inhibited by various synthetic protease inhibitors, for example, N-acyl benzisothiazolones and the respective 1,1-dioxides. Morris Zimmerman et al., J. Biol. Chem., 255, 9848 (1980); and

(3) There is an appearance and/or presence of lymphoid cells, especially macrophages and polymorphonuclear leukocytes (PMN). It has been known that a variety of proteases are released from the macrophages and PMN, further indicating that the proteases do play an important role in inflammation.

In general, proteases are an important family of enzymes within the peptide bond cleaving enzymes whose members are essential to a variety of normal biological activities, such as digestion, formation and dissolution of blood clots, the formation of active forms of hormones, the immune reaction to foreign cells and organisms, etc., and in pathological conditions such as the degradation of structural proteins at the articular cartilage/pannus junction in rheumatoid arthritis etc.

Elastase is one of the proteases. It is an enzyme capable of hydrolyzing the connective tissue component elastin, a property not contained by the bulk of the proteases present in mammals. It acts on a protein's nonterminal bonds which are adjacent to an aliphatic amino acid. Neutrophil elastase is of particular interest because it has the broadest spectrum of activity against natural connective tissue substrates. In particular, the elastase of the granulocyte is important because, as described above, granulocytes participate in acute inflammation and in acute exacerbation of chronic forms of inflammation which characterize many clinically important inflammatory diseases.

Proteases may be inactivated by inhibitors which block the active site of the enzyme by binding tightly thereto. Naturally occurring protease inhibitors form part of the control or defense mechanisms that are crucial to the well-being of an organism. Without these control mechanisms, the proteases would destroy any protein within reach. The naturally occurring enzyme inhibitors have been shown to have appropriate configurations which allow them to bind tightly to the enzyme. This configuration is part of the reason that inhibitors bind to the enzyme so tightly (see Stroud, "A Family of Protein-Cutting Proteins" Sci. Am. July 1974, pp. 74-88). For example, one of the natural inhibitors, α1 -Antitrypsin, is a glycoprotein contained in human serum that has a wide inhibitory spectrum covering, among other enzymes, elastase both from the pancreas and the PMN. This inhibitor is hydrolyzed by the proteases to form a stable acyl enzyme in which the active site is no longer available. Marked reduction in serum α1 -antitrypsin, either genetic or due to oxidants, has been associated with pulmonary emphysema which is a disease characterized by a progressive loss of lung elasticity and resulting respiratory difficulty. It has been reported that this loss of lung elasticity is caused by the progressive, uncontrolled proteolysis or destruction of the structure of lung tissue by proteases such as elastase released from leukocytes. J. C. Powers, TIBS, 211 (1976).

Rheumatoid arthritis is characterized by a progressive destruction of articular cartilage both on the free surface bordering the joint space and at the erosion front built up by synovial tissue toward the cartilage. This destruction process, in turn, is attributed to the protein-cutting enzyme elastase which is a neutral protease present in human granulocytes. This conclusion has been supported by the following observations:

(1) Recent histochemical investigations showed the accumulation of granulocytes at the cartilage/pannus junction in rheumatoid arthritis; and

(2) a recent investigation of mechanical behavior of cartilage in response to attack by purified elastase demonstrated the direct participation of granulocyte enzymes, especially elastase, in rheumatoid cartilage destruction. H. Menninger etal., in Biological Functions of Proteinases, H. Holzer and H. Tschesche, eds. Springer-Verlag, Berlin, Heidelberg, New York, pp. 196-206, 1979.

In a second aspect this invention concerns the use of novel azetidinones in the treatment of certain cancers including nonlymphoblastic leukemias, acute myelogenous leukemia (FAB M1 and FAB M2), acute promyelocytic leukemia (FAB M3), acute myelomonocytic leukemia (FAB M4), acute monocytic leukemia (FAB M5), erythroleukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic monocytic leukemia and conditions associated with leukemia involving activity of PMN neutral proteases e.g. disseminated intravascular coagulation. We have found that the substituted azetidinones disclosed herein are inhibitors of proteinase 3 (PR-3), also known as myeloblastin.

See C. Labbaye, et al., Proc. Natl. Acad. Sci. USA, vol. 88, 9253-9256, (1991), Wegner autoantigen and myeloblastin are encoded by a single mRNA; D. Campanelli, et al., J. Exp. Med., vol. 172, 1709-1714, (1990), Cloning of cDNA for proteinase 3: A serine protease, antibiotic, and autoantigen from human neutrophils; and Bories, st. al., Cell vol. 59, 959-968, (1989) Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells.

Recently, down regulation of PR-3 has been implicated in the proliferation and maintenance of a differentiated state of certain leukemia cells. In particular, Bories, et. al., have shown that expression of this enzyme, hereinafter designated proteinase 3/myeloblastin, can be inhibited by treatment of HL-60 human leukemia cells with an antisense oligodeoxynucleotide and that such treatment induces differentiation and inhibits proliferation of these cells. Moreover, we have now demonstrated that the treatment of the HL-60 cell human leukemia cell line, among others, with the compounds of the instant invention, likewise results in the inhibition of proliferation and induction of differentiation in such cells.

Accordingly, we believe that treatment of leukemia such as nonlymphoblastic leukemias, acute myelogenous leukemia (FAB M1 and FAB M2), acute promyelocytic leukemia (FAB M3), acute myelomonocytic leukemia (FAB M4), acute monocytic leukemia (FAB M5), erythroleukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic monocytic leukemia and conditions associated with leukemia involving activity of PMN neutral proteases e.g. disseminated intravascular coagulation, comprising: administration of a therapeutically effective amount of compound of Formula I will result in remission of the disease state. Administration may be either oral or parenteral.

BRIEF DESCRIPTION OF THE INVENTION

The instantly claimed invention is directed to specifically substituted azetidinones of Formula I ##STR6##

These substituted azetidinones have been found to be useful anti-inflammatory and antidegenerative agents. This invention is also directed to pharmaceutical compositions and methods of using these specifically substituted azetidinones.

These compounds will also be useful in the treatment of certain leukemias and leukemia related conditions.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to potent-elastase inhibitors of Formula (I), ##STR7## which are useful in the prevention, control and treatment of inflammatory and degenerative conditions especially arthritis and emphysema.

More particularly, the instant invention is directed to the compounds of the Formula (I) ##STR8## and pharmaceutically acceptable salts thereof wherein: R is C1-6 alkyl;

R1 is C1-6 alkyl or C1-6 alkoxy-C1-6 alkyl;

M is

(1) hydrogen,

(2) C1-6 alkyl,

(3) hydroxy C1-6 alkyl,

(4) halo C1-6 alkyl,

(5) C2-6 alkenyl, or

(6) C1-6 alkoxy-C1-6 alkyl;

Ra and Rb are each individually

(1) hydrogen,

(2) C1-6 alkyl,

(3) halo,

(4) carboxy,

(5) C1-6 alkoxy,

(6) phenyl,

(7) C1-6 alkylcarbonyl,

(8) di-(C1-6 alkyl)amino;

(9) hydroxy;

R2 and R3 are each independently

(1) hydrogen,

(2) C1-6 alkyl,

(3) halo,

(4) carboxy,

(5) C1-6 alkoxy,

(6) phenyl,

(7) C1-6 alkylcarbonyl,

(8) aminoC2-3 alkyloxy carbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(9) aminoC2-3 alkylamino carbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(10) hydroxy,

(11) aminocarbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(12) hydroxymethyl,

(13) aminocarbonyloxy C1-3 alkyloxy wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(14) cyano,

(15) morpholinocarbonylphenyl,

(16) amino wherein the amino is optionally mono or di substituted with C1-6 alkyl, with the proviso that R2 and R3 may be joined together to form a methylenedioxy group or a furan ring,

(17) morpholinocarbonyl;

R4 is (a) ##STR9## or (b) ##STR10## where Rx is carboxy C1-6 alkyl, benzyloxycarbonylC1-3 alkyl, or t-butoxycarbonylC1-3 alkyl,

wherein

Q is a covalent bond or ##STR11## wherein R5 and R6 are each individually C1-3 alkyl or,hydrogen,

Y is ##STR12## or a covalent bond; R12 is hydrogen or C1-3 alkyl;

R7 and R8 are each individually

(a) hydrogen,

(b) C1-6 alkyl,

(c) C1-6 alkyloxy C2-3 alkyl,

(d) hydroxy C2-6 alkyl,

(e) polyhydroxyC2-6 alkyl,

(f) carboxamido C1-6 alkyl,

(g) polyacyloxyC2-6 alkyl

(h) C1-6 alkanoyl,

(i) substituted phenyl or phenyl C1-6 alkyl, wherein the substitutent is X1 as defined immediately below,

(j) C2-6 alkenyl,

(k) C6-10 cycloalkenyl,

(l) heteroaryl C1-6 alkyl wherein the hetero aryl includes pyridinyl, imidazolyl, triazolyl, benzylimidazolyl, and furyl,

(m) carboxy C1-6 alkyl,

(n) carbo C1-6 alkoxy C1-3 alkyl,

(o) phenylsulfonyl,

(p) C1-6 alkylsulfonyl,

(q) benzyloxy,

(r) morpholinyl C1-3 alkylsulfonyl,

(s) tetrahydropyranyl,

(t) aminoC1-3 alkylsulfonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(u) aminocarbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(v) aminocarbonyloxyC2-6 alkyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(w) azabicyclo of 7 to 12 atoms,

(x) di C1-3 alkylamino C2-6 alkyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(y) bicycloalkyl of 7 to 12 atoms,

(z) C3-10 cycloalkyl optionally substituted with C1-6 alkyl,

(aa) pyrazolidinyl,

(bb) substituted piperidinyl or prrrolidinyl wherein the substitutent is hydrogen, C1-3 alkyl, hydroxyC1-3 alkylbenzyl, carboxamido or amino wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(cc) substituted pyrrolidinyl wherein the substitutent is carboxamido or amino wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(dd) pyrimidinyl,

(ee) N-cyano-N'-phenylamidino,

(ff) phosphonoC1-6 alkyl, or

(gg) α-C1-3 alkyl benzyl or mono or di substituted benzyl or mono or di substituted pyridylmethyl, wherein the substitutents are X1 and X2,

wherein

X1 is

(1) hydrogen,

(2) halo,

(3) C1-6 alkyl,

(4) halo-C1-6 alkyl,

(5) C2-6 alkenyl,

(6) hydroxy-C1-6 alkyl,

(7) C1-6 alkylcarbonyl,

(8) C1-6 alkylcarbonylamino;

(9) CN,

(10) CF3,

(11) CH3 O,

(12) amino wherein the amino is optionally mono or di substituted with C1-6 alkyl;

(13) carboxy, or

(14) phenylsulfonylaminocarbonyl; X2 is hydrogen, halo or C1-6 alkyl;

n is 1, 2, 3, 4 or 5;

R9 is selected from hydrogen, C1-4 alkyl, and C1-3 alkoxyC1-3 alkyl; or phenyl, phenyl C1-3 alkyl, pyridyl, and pyridyl C1-3 alkyl;

R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl, or aryl as defined above, or are together O═; or

wherein

R7 and R8 are joined together to form mono or di substituted ring of 4, 5, 6, or 7 atoms or 7 to 12 atoms such as

(1) piperidinyl or homopiperdinyl,

(2) piperazinyl,

(3) morpholinyl, thiomorpholinyl or 1,1-dioxo-4-thiomorpholinyl,

(4) pyrroylidinyl,

(5) pyrryl,

(6) imidazolyl,

(7) triazolyl,

(8) saturated azabicyclo of 7 to 12 atoms

(9) azaspiro having 3 to 9 carbon atoms, said ring being saturated,

(10) tetrazolyl,

(11) pyrazolidinyl,

(12) dihydodimethoxyisoquinolyl,

(13) azetidinyl, or

(14) diazabicyclo ring of 7-12 atoms,

wherein the substituents are each selected from the group consisting of hydrogen and C1-3 alkyl, benzyloxycarbonyl, carboxy, phenyl C1-3 alkyl amino carbonyl, pyrrolidinylmethyl, hydroxy C1-3 alkyl, C1-6 alkyloxy, C1-4 alkyloxy carbonyl, aminocarbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl, and oxo; or --N(R7)R8 may be an amino acid residue including natural amino acids such as lysine; or R8 and R9 are joined together to form a mono or di substituted saturated monocyclic ring of 6 to 7 atoms and having two hetero atoms which are the nitrogens to which R8 and R9 are attached; said rings to include piperazinyl and homopiperazinyl; or R9 and R10 are joined together to form a mono or di substituted monocyclic saturated ring of 5 to 7 atoms and having one hetero atom which is the nitrogen to which R9 is attached; or

wherein R9 and R12 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R9 is attached; or wherein R10 and R12 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 carbon atoms; or

wherein R8 and R11 are joined together to form a mono or di substituted saturated monocyclic ring of 5, 6, or 7 atoms, said ring having one hetero atom which is the nitrogen to which R8 is attached; and the substituents are independently selected-from Hydrogen and C1-3alkyl.

As appreciated by those of Skill in the art the term "alkyl" such as in C1-6 alkyl, includes, methyl, ethyl, propyl, butyl, pentyl, and hexyl, and where appropriate, branched chained forms including isopropyl and tert-butyl.

As may also be appreciated by those of skill in the art, the ##STR13## spacer in definition Y, may, in the alternative be placed to the right of CR10 R11.

As may also be appreciated, the group ##STR14## may also be oxidized to the corresponding oxide ##STR15##

In one Class the instant invention is directed to the compounds of the Formula (I) ##STR16## and pharmaceutically acceptable salts thereof wherein: R is C1-6 alkyl;

R1 is C1-6 alkyl or C1-6 alkoxy-C1-6 alkyl;

M is

(1) hydrogen,

(2) C1-6 alkyl,

(3) hydroxy C1-6 alkyl,

(4) halo C1-6 alkyl,

(5) C2-6 alkenyl, or

(6) C1-6 alkoxy-C1-6 alkyl;

Ra is

(1) hydrogen,

(2) C1-6 alkyl,

(3) halo,

(4) carboxy,

(5) C1-6 alkoxy,

(6) phenyl,

(7) C1-6 alkylcarbonyl,

(8) amino wherein the amino is optionally mono or di substituted with C1-6 alkyl;

Rb is hydrogen, or C1-6 alkyl,

R2 and R3 are each independently

(1) hydrogen,

(2) C1-6 alkyl,

(3) halo,

(4) carboxy,

(5) C1-6 alkoxy,

(6) phenyl,

(7) C1-6 alkylcarbonyl,

(8) amino wherein the amino is optionally mono or di substituted with C1-6 alkyl, or with the proviso that R2 and R3 may be joined together to form a methylenedioxy group or a furan ring;

R4 is (a) ##STR17## or (b) ##STR18## where Rx is carboxyC1-6 alkyl, benzyloxycarbonylC1-3 alkyl, or t-butoxycarbonylC1-3 alkyl,

wherein

Q is a covalent bond or ##STR19## wherein R5 and R6 are each individually C1-3 alkyl or hydrogen

Y is ##STR20## or a covalent bond; R12 is hydrogen or C1-3 alkyl;

R7 and R8 are each individually

(a) hydrogen,

(b) C1-6 alkyl,

(c) C1-6 alkyloxy C2-3 alkyl,

(d) hydroxy C2-6 alkyl,

(e) carboxamido C1-6 alkyl,

(f) C1-6 alkanoyl,

(g) substituted phenyl or phenyl C1-6 alkyl wherein the substitutents are X1, and X2

(h) C2-6 alkenyl,

(i) C6-10 cycloalkenyl,

(j) heteroaryl C1-6 alkyl wherein the hetero aryl includes pyridinyl, imidazolyl, triazolyl, benzylimidazolyl, and furyl,

(k) carboxy C1-6 alkyl,

(l) C1-6 alkylsulfonyl,

(m) carboC1-6 alkyloxyC2-3 alkyl,

(n) morpholinyl C1-3 alkylsulfonyl,

(o) aminoC1-3 alkylsulfonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(p) aminocarbonyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(q) aminocarbonyloxyC1-6 alkyl wherein the amino,is optionally mono or di substituted with C1-6 alkyl,

(r) di C1-3 alkylamino C1-6 alkyl wherein the amino is optionally mono or di substituted with C1-6 alkyl,

(s) pyrazolidinyl,

(t) substituted piperidinyl as defined above,

(u) substituted pyrrolidinyl as defined above

(v) pyrimidinyl,

(w) benzyloxy,

(x) C3-10 cycloalkyl,

(z) α-C1-3 alkyl benzyl or mono or di substituted benzyl or-mono or di substituted pyridylmethyl, wherein the substitutents are X1 and X2,

wherein

X1 is

(1) hydrogen,

(2) halo,

(3) C1-6 alkyl,

(4) halo-C1-6 alkyl,

(5) C2-6 alkenyl,

(6) hydroxy-C1-6 alkyl,

(7) C1-6 alkylcarbonyl,

(8) C1-6 alkylcarbonylamino;

(9) di-C1-3 alkylamino; or

(10) carboxy,

X2 is hydrogen, halo or C1-6 alkyl;

n is 1, 2, 3, 4 or 5;

R9 is selected from hydrogen, C1-4 alkyl, and C1-3 alkoxyC1-3 alkyl;

R10 nd R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl; or

wherein

R7 and R8 are joined together to form mono or di substituted ring of 4, 5, 6, or 7 atoms such as

(1) piperidinyl,

(2) piperazinyl,

(3) morpholinyl,

(4) pyrroylidinyl,

(5) pyrryl,

(6) imidazolyl,

(7) triazolyl,

(8) tetrazolyl,

(9) pyrazolidinyl,

(10) azetidinyl,

wherein the substituents are each selected from the group consisting of hydrogen and C1-3 alkyl, benzyloxycarbonyl, carboxy, phenyl C1-3 alkyl amino carbonyl, pyrrolidinyl, methyl, hydroxy C1-3 alkyl, C1-6 alkyloxy, C1-4 alkyloxy carbonyl, and oxo; or R8 and R9 are joined together to form a saturated ring of 5 to 7 atoms and having two hetero atoms; or R9 and R10 are joined together to form a saturated ring of 5 to 7 atoms and having one hetero atom; or wherein R9 and R12 are joined together to form a ring of 5, 6, or 7 atoms, said ring being saturated; or wherein R10 and R12 are joined together to form a ring of 5, 6, or 7 atoms, said ring being saturated; or

wherein R8 and R11 are joined together to form a ring of 5, 6, or 7 atoms, said ring being saturated and having one hetero atom.

In one subclass, the invention concerns compounds of Formula I

wherein

R is C1-3 alkyl;

R1 is C1-3 alkyl;

M is

(a) C1-6 alkyl, or

(b) C2-6 alkenyl;

R2 is

(a) hydrogen,

(b) C1-6 alkyl, or C1-6 alkoxy, and

R3 is hydrogen, or

R2 and R3 are joined together to form a methylenedioxy group or a furan ring; R5 and R6 are each individually hydrogen or C1-3 alkyl;

R7 and R8 are each independently selected from

(a) hydrogen,

(b) C1-3 alkyl,

(c) C1-3 alkoxy C2-3 alkyl,

(d) C3-7 cycloalkyl,

(e) hydroxyC2-3 alkyl,

(d) carbo C1-4 alkyloxymethyl,

(g) substituted benzyl wherein the substituents are X1 and X2

wherein X1 is hydrogen and X2 is

(1) hydrogen,

(2) halo, or

(3) C1-3 alkyl;

n is 1, 2 or 3, and

R9, R10 and R11 are each independently selected from hydrogen, C1-4 alkyl, and C1-3 alkoxy C1-3 alkyl; or

R7 and R8 are joined together to form a substituted ring selected from

(a) piperidinyl,

(b) piperazinyl, and

(c) morpholinyl;

or

R8 and R9 are joined together to form a ring of 6 to 7 atoms and having two hetero atoms;

R9 and R10 are joined together to form a saturated ring of 5 to 7 atoms and having one hetero atom; or wherein R9 and R12 are joined together to form a ring of 5, 6, or 7 atoms, said ring being saturated; or wherein R10 and R12 are joined together to form a ring of 5, 6, or 7 atoms, said ring being saturated; or

wherein R8 and R11 are joined together to form a ring of 5, 6, or 7 atoms, said ring being saturated and having one hetero atom.

In a narrower sub-class are the compounds wherein

Q is a covalent bond;

R is methyl or ethyl;

R1 is methyl or ethyl;

M is

(a) C1-4 alkyl, or

(b) C2-3 alkenyl;

R2 is

(a) hydrogen,

(b) C1-3 alkyl, or C1-3 alkoxy, and

R3 is hydrogen, or

R2 and R3 are joined together to form a furan or dioxacyclopentane ring;

n is 1 or 2;

R9 and R10 are each independently selected from

(a) C1-3 alkyl,

(b) C1-3 alkoxy C1-3 alkyl,

(c) hydrogen,

R7 and R8 are each independently selected from

(a) C1-3 alkyl,

(b) C1-3 alkoxy C2-3 alkyl,

(c) hydrogen,

(d) hydroxyethyl,

(e) carboethoxymethyl,

(f) cyclopropyl, or

R7 and R8 are joined together to form a substituted ring selected from

(a) piperidinyl, and

(b) morpholinyl, or

R8 and R9 are joined together to form a piperazine ring.

In another aspect the present invention is directed to the treatment of leukemia, such as nonlymphoblastic leukemias, acute myelogenous leukemia (FAB M1 and FAB M2), acute promyelocytic leukemia (FAB M3), acute myelomonocytic leukemia (FAB M4), acute monocytic leukemia (FAB M5), erythroleukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic monocytic leukemia and conditions associated with leukemia involving activity of PMN neutral proteases e.g. disseminated intravascular coagulation with compounds of Formula I.

Treatment of leukemia cells comprises: administration of a therapeutically effective amount of a compound of Formula I results in the inhibition of proteinase 3/myeloblastin, inhibition of elastase, inhibition of proliferation of the leukemia cells, induction of differentiation of the leukemia cells, and remission of the disease state.

In one alternative embodiment the invention concerns a method of treating leukemia comprising: administration to a patient in need of such treatment of a therapeutically effective amount of compound of Formula I.

In a second alternative embodiment the invention concerns a method of inhibiting proteinase 3/myeloblastin, comprising: administration to a patient in need of such inhibition of a therapeutically effective amount of compound of Formula I as defined above.

In a third alternative embodiment the invention concerns a method of inhibiting proteinase 3/myeloblastin and elastase, comprising: administration to a patient in need of such inhibition of a therapeutically effective amount of compound of Formula I as or a pharmaceutically acceptable salt thereof as defined above.

In a fourth embodiment the invention concerns a method of inducing cellular differentiation in leukemia cells comprising: administration to a patient in need of such inhibition of a therapeutically effective amount of compound of Formula I or a pharmaceutically acceptable salt thereof as defined above.

Each of the above alternative embodiments (i.e., those relating to PR3 or cancer), also concerns co-administration of a compound of Formula I as defined above, with an agent or agents known in the art for treatment of leukemia, including, but not limited to epsilon-aminocaproic acid, heparin, trasylol (aprotinin); prednisolone; cytosine arabinoside; β-mercaptopurine; cytarabine; an anthracycline (see Young et. al. (1981) N. Engl. J. Med. 305:139) such as daunorubicin, doxorubicin and epidoxorubicin; Vitamin A derivatives including retinoids and all-trans-retinoic acid (See Ellison R. R. et.al. (1968) Blood 32:507, Arabinosyl Cytosine: A useful agent in the treatment of leukemia in adults; Cytarabine: Therapeutic new dimensions, Semin. Oncol. 12:1 (1985, supp 3); Weinstein H. J. et. al. (1983) Blood 62:315, Chemotherapy for acute myelogenous leukemia in children and adults results in an enhanced therapeutic response.

Accordingly, in a fifth alternative embodiment the invention concerns a pharmaceutical composition comprising: a pharmaceutical carrier, a therapeutically effective amount of compound selected from the group consisting of epsilon-aminocaproic acid, heparin, trasylol, prednisolone, cytosine arabinoside, β-mercaptopurine, cytarabine, an anthracycline and a vitamin A derivative; and a therapeutically effective amount of compound of Formula I as defined above.

In a sixth alternative embodiment the invention concerns a method of treating leukemia comprising: co-administration to a patient in need of such treatment of a therapeutically effective amount of compound selected from the group consisting of epsilon-aminocaproic acid, heparin, trasylol, prednisolone, cytosine arabinoside, b-mercaptopurine, cytarabine, an anthracycline, and a vitamin A derivative; and a therapeutically effective amount of compound of Formula I as defined above.

In a seventh alternative embodiment the invention concerns a method of inhibiting proteinase 3/myeloblastin, comprising:

co-administration to a patient in need of such inhibition of a therapeutically effective amount of compound selected from the group consisting of epsilon-aminocaproic acid, heparin, trasylol, prednisolone, cytosine arabinoside, β-mercaptopurine, cytarabine, an anthracycline, and a vitamin A derivative;and a therapeutically effective amount of compound of Formula I as defined above.

In an eighth alternative embodiment the invention concerns a method of inhibiting proteinase 3/myeloblastin and elastase, comprising: administration to a patient in need of such inhibition of a therapeutically effective amount of compound selected from the group consisting of epsilon-aminocaproic acid, heparin, trasylol, prednisolone, cytosine arabinoside, β-mercaptopurine, cytarabine, an anthracycline, and a vitamin A derivative; and a therapeutically effective amount of compound of Formula I as defined above.

In a ninth alternative embodiment the invention concerns a method of inducing cell differentiation in leukemia cells comprising: administration to a patient in need of such inducing of a therapeutically effective amount of compound selected from the group consisting of epsilon-aminocaproic acid, heparin, trasylol, prednisolone, cytosine arabinoside, β-mercaptopurine, cytarabine, an anthracycline and a vitamin A derivative; and a therapeutically effective amount of compound of Formula I as defined above.

The compounds of the invention are prepared by known methods or are prepared among other methods by the following representative schemes. For example, methods for making such compounds are disclosed in EP 0 337 549, published Oct. 18, 1989, which is hereby incorporated by reference.

This invention also relates to a method of treating inflammation in patients using a compound of Formula (I), particularly a preferred compound as the active constituent.

It has been found that the following compound are effective inhibitors of the proteolytic function of human neutrophil elastase as shown below in Table 1 to 10.

TABLE 1
______________________________________
##STR21##
No. A Kobs/[I]
______________________________________
1 CH2 CH2 N(CH3)2
1,566,000
2 CH2 CO2 H 1,667,000
3 CH2 C(O)N(CH2 CH2 OH)2
3,428,000
4 CH2 C(O)N(CH3)CH2 C(O)NH2
4,293,000
5 CH2 C(O)NHC(CH2 OH)3
4,448,000
6 CH2 C(O)N(CH3)2
2,997,000
7 CH2 CH2 N(CH3)Ac
1,558,000
8 CH2 C(O)-Pro-OCH2 Ph
12,501,000
9 CH2 C(O)-Pro-OH 1,571,000
10 CH(CH3)CO2 CH2 Ph
2,891,000
11 CH(CH3)CO2 H 1,132,000
12 CH(CH3)C(O)N(Et)2
2,815,000
13 CH(CH3)CH2 N(CH3)2
2,472,000
14 CH2 CH2 CH2 N(CH3)2
2,855,000
15 CH2 CH2 N(O)(CH3)2
2,162,000
16 CH2 CH2 N(Et)2
2,291,000
17 CH2 CH2 (4-morpholinyl)
4,733,000
18 CH2 CH2 CH2 CH2 N(CH3)2
1,934,000
19 CH2 C(O)-Pro-NHCH2 Ph
4,956,000
20 CH2 C(CH3)2 N(CH3)2
1,470,000
21 CH2 CH2 N(i-Pr)2
1,671,000
22 CH2 CH2 (4-carbobenzyloxy-1-piperazinyl)
4,115,000
23 CH2 CH2 N(n-Bu)2
992,000
24 CH2 CH2 CH2 CH2 CH2 CH2 N(CH3).sub
.2 1,988,000
25 CH2 CH2 (1-piperazinyl)
1,709,000
26 CH2 CH2 (4-methyl-1-piperazinyl)
4,685,000
27 CH2 CH2 (4-acetyl-1-piperazinyl)
3,262,000
28 CH2 CH2 N(Ph)2
188,000
29 CH2 CH2 N(CH2 CHCH2)2
891,000
30 CH2 CH(Ph)N(CH3)2
656,000
31 CH2 CH2 N(CH3)CH2 Ph
1,180,000
______________________________________
TABLE 2
______________________________________
##STR22##
No. A Kobs/[I]
______________________________________
32 CH2 CH2 N(CH3)2
1,993,000
33 CH2 CH2 CH2 N(CH3)2
1,151,000
34 CH2 CH2 N(Et)2
1,339,000
35 CH2 CH2 -(4-morpholinyl)
1,725,000
36 CH(CH3)CH2 N(CH3)2
1,688,000
37 CH2 C(CH3)2 N(CH3)2
2,100,000
38 CH2 CO2 H
1,008,000
39 CH2 CH2 N(CH3)CH2 Ph
751,000
______________________________________
TABLE 3
______________________________________
##STR23##
No. A Kobs/[I]
______________________________________
40 N(CH2 CH2 OH)2
1,241,000
41 4-methyl-1-piperazinyl 974,000
42 4-morpholinyl 1,088,000
43 NHCH2 CH2 N(CH3)2
1,211,000
44 N(CH3)CH2 CH2 N(CH3)2
1,243,000
45 NHCH2 CH2 CH2 N(CH3)2
1,118,000
46 NHCH2 CH2 -(4-pyridyl)
2,254,000
47 NHCH2 CO2 H 876,000
48 NHCH(CH3)CO2 H
676,000
49 NHCH2 C(O)N(CH2 CH2 OH)2
1,295,000
50 N(CH3)CH2 CO2 H
989,000
51 NHCH(CH3)C(O)N(CH2 CH2 OH)2
939,000
52 N(CH3)CH2 C(O)N(CH2 CH2 OH)2
273,000
53 N(CH3)CH2 CH2 -(4-morpholinyl)
2,511,000
54 N(CH3)CH2 CH2 N(CH2 CH2 OCH3)2
1,388,000
55 N(CH3)CH2 CH2 N(Et)2
1,316,000
56 N(CH3)CH2 CH2 CH2 N(CH3)2
1,047,000
57 NHCH2 CH(CH3)N(CH3)2
1,344,000
58 N(CH3)CH2 CH2 N(i-Pr)2
1,634,000
59 N(n-Pr)2 1,144,000
60 N(Et)2 1,079,000
61 3-chloroanilino- 733,000
62 3-methoxyanilino- 1,621,000
63 4-fluoroanilino-
64 N(CH3)CH2 CH2 CH2 CO2 H
917,000
65 N(CH3)CH2 CH2 CH2 C(O)NHSO2 Ph
1,335,000
66 N(CH3)CH2 CH2 CH2 N(CH3)CH2 Ph
1,355,000
67 N(CH3)2 942,000
68 N(CH3)CH2 Ph 1,897,000
69 N(CH3)CH2 CH2 N(CH3)CH2 Ph
2,792,000
70 NHOCH2 Ph 2,371,000
71 N(CH3)(4-carboxyphenyl)
1,508,000
72 N(CH3)(4-benzenesulfonyl-
3,284,000
amino-carbonylphenyl)
______________________________________
TABLE 4
______________________________________
##STR24##
No. A Kobs/[I]
______________________________________
73 NHCH2 CH2 N(CH3)2
968,000
74 NHCH2 CO2 H 1,434,000
75 N(CH3)CH2 CH2 N(CH3)2
1,916,000
76 N(Et)CH2 CH2 N(CH3)2
1,436,000
77 NHCH2 CH2 N(Et)2
1,187,000
78 NHCH2 CH2 -(4-morpholinyl)
1,841,000
79 N(CH3)CH2 CH2 -(4-morpholinyl)
2,118,000
80 N(CH3)CH2 CH2 N(CH2 CH2 OCH3)2
2,078,000
81 N(CH3)CH2 CH2 N(Et)2
2,191,000
82 N(Ph)CH2 CH2 N(CH3)2
2,504,000
83 N(CH3)CH2 CH2 CH2 N(CH3)2
1,797,000
84 NHCH2 CH2 N(i-Pr)2
2,100,000
85 N(CH3)CH2 CH2 N(O)(CH3)2
1,589,000
86 N(CH3)CH2 CH2 N(i-Pr)2
2,449,000
87 NHSO2 CH2 CH2 -(4-morpholinyl)
775,000
88 NHSO2 CH2 CH2 N(CH3)2
788,000
89 NHCH2 CH2 -(4-imidazolyl)
2,092,000
90 NHCH2 CH2 -(1-piperidinyl)
941,000
91 N(CH3)CH2 CH2 -(1-piperidinyl)
892,000
92 N(CH3)CH2 CH2 NHCH3
1,453,000
93 N(CH3)CH2 CH2 N(CH3)Ac
1,960,000
94 NHCH2 CH2 -(1-pyrrolidinyl)
1,239,000
95 N(CH3)CH2 CH2 -(1-pyrrolidinyl)
1,005,000
96 NHCH2 CH2 -(1H-1,2,4-triazol-1-yl)
1,397,000
97 NHCH2 CH2 -(1-imidazolyl)
1,070,000
98 NHCH2 CH2 -(3-azabicyclo-[3.2.2-non-3-yl)
3,043,000
99 NHCH2 CH2 -(3-azaspiro[5.5]-undec-3-yl)
2,583,000
100 NHCH2 CH2 -(2H-tetrazol-2-yl)
2,006,000
101 NHCH2 CH2 -(1H-tetrazol-1-yl)
2,053,000
102 NHCH2 C(O)-Pro-NHCH2 Ph
2,747,000
103 N(CH3)CH2 CH2 -(3-azabicyclo-
2,996,000
[3.2.2]non-3-yl)
104 N(CH3)CH2 CH2 -(4-imidazolyl)
2,389,000
105 N(CH3)CH2 CH2 N(CH3)Ac
2,398,000
106 N(CH3)CH2 CH2 N(CH3)C(O)NHCH3
2,486,000
107 N(CH3)CH2 CH2 N(CH3)SO2 CH3
2,530,000
108 N(CH3)CH2 CH2 (3-azabicyclo-[3.2.2]-
2,953,000
non-3-yl)
109 NHCH2 CH2 -(1,1-dioxo-4-thiamorpholinyl)
1,275,000
110 4-dimethylaminobenzylamino 5,598,000
111 3-dimethylaminoanilino 2,286,000
112 N(CH3)CH2 CH2 -(1,1-dioxo-4-thia-
1,596,000
morpholinyl)
113 4-dimethylaminoanilino 2,591,000
114 NHCH2 CH2 -(1-benzyl-1H-imidazol-2-yl)
3,853,000
115 N(CH3)CH2 CH2 (2-pyridyl)
2,272,000
116 N(CH3)(1-azabicyclo[2.2.2]oct-3-yl
3,480,000
117 NHCH2 CH2 (4-benzyloxycarbonyl-1-
6,231,000
piperazinyl)
118 1,2-diethylpyrazolidin-4-ylamino
1,001,000
119 2-(1- S-pyrrolidinylmethyl)-1-pyrrolidinyl
2,692,000
120 NHCH2 CH2 (4-hydroxy-1-piperidinyl)
1,728,000
121 NHCH2 CH2 (1-homopiperidinyl)
2,069,000
122 N(CH3)CH2 CH2 (1-homopiperidinyl)
2,899,000
123 NHCH2 CH2 (3-hydroxy-1-piperidinyl)
1,534,000
124 N(CH3)CH2 CH2 (3-hydroxy-1-piperidinyl)
1,963,000
125 N(CH3)CH2 CH2 N(CH3)CH2 Ph
2,054,000
126 N(CH3)CH2 CH2 (4-benzyloxy-1-piperidinyl)
3,476,000
127 N(n-Pr)2 990,000
128 N(Et)2 1,454,000
129 N(CH3)CH2 CH2 (4-hydroxy-1-piperidinyl)
1,994,000
130 N(CH3)CH2 CH2 (4-oxo-1-piperidinyl)
2,297,000
131 NHCH2 CH2 (3-hydroxy-1-pyrrolidinyl)
1,111,000
132 N(Et)CH2 CH2 (1-piperidinyl)
1,244,000
133 N(CH2 Ph)CH2 CH2 (1-piperidinyl)
1,521,000
134 4-fluoroanilino- 724,000
135 3-chloroanilino- 201,000
136 3-methoxyanilino
137 N(CH2 Ph)CH2 CH2 N(CH3)2
1,380,000
138 N(CH3)CH2 CH2 (3-hydroxy-1-pyrrolidinyl)
960,000
139 N(3-picolyl)CH2 CH2 (1-piperidinyl)
1,189,000
140 NHCH(CH3)CH2 CH2 CH2 N(Et)2
1,361,000
141 NHCH2 CH2 (2- S-hydroxymethyl-1-
1,507,000
pyrrolidinyl
142 N(CH3)CH2 CH2 (4-t-butoxycarbonyl-1-
3,471,000
piperazinyl)
143 N[CH2 CH2 N(CH3)2 ]2
1,878,000
144 N[CH2 CH2 N(Et)2 ]2
1,508,000
145 N(CH3)CH2 CH2 N(CH3)(3-picolyl)
2,877,000
146 3,5-dimethyl-1-piperazinyl 1,518,000
147 N(CH3)CH2 CH2 N(O)(CH3)CH2 Ph
2,493,000
148 N(CH3)CH2 CH2 N(CH3)(4-picolyl)
2,389,000
149 2- S-(N-benzylN-methylaminomethyl)-1-
3,268,000
pyrrolidinyl
150 N(CH3)CH2 CH2 N(CH3)(2-picolyl)
2,165,000
151 N(CH3)CH2 CH2 (1-piperazinyl)
1,191,000
152 1-homopiperazinyl 1,951,000
153 N(CH3)CH2 CH2 N(CH3)CH2 CH2 Ph
2,797,000
154 2-(1-R-pyrrolidinylmethyl)-1-pyrrolidinyl
1,666,000
155 4-benzyl-1-homopiperazinyl 1,979,000
156 N(CH3)CH2 [CH(OH)]4 CH2 OH
1,198,000
157 N(CH3)CH2 [CH(OAc)]4 CH2 OAc
1,171,000
158 N(CH3)CH2 CH2 N(CH3)(1-Naphthalenyl-
1,075,000
methyl)
159 N(CH3)CH2 CH2 N(CH3)(2-Naphthalenyl-
1,337,000
methyl)
160 N(CH3)CH2 CH2 N(CH3)CH(CH3)Ph
1,569,000
161 N(CH3)CH2 CH2 N(CH2 Ph)2
1,021,000
162 1-ethyl-3-piperidinylamino 949,000
163 N(CH3)CH2 CH2 N(CH3)(2-furfuryl)
1,818,000
164 N(CH3)CH2 CH2 CH2 CO2 H
1,064,000
165 N(CH3)CH2 CH2 CH2 C(O)NHSO2 Ph
1,550,000
166 N(CH3)CH2 CH2 N(CH3)CH2 CHCH2
1,359,000
167 N(CH3)CH2 CH2 CH2 N(CH3)CH2 Ph
1,293,000
168 N(CH3)(CH2)6 N(CH3)CH2 Ph
2,157,000
169 N(CH3)CH2 CH2 OH
1,457,000
170 N(CH3)CH2 CH2 OC(O)N(CH3)2
1,518,000
171 N(CH3)CH2 CH2 N(CH3)CH2 CO2 -t-Bu
1,831,000
172 N(CH3)(1-ethyl-3-piperidinyl)
1,545,000
173 N(CH3)CH2 CH2 N(CH3)(tetrahydro-2H-
2,943,000
pyran-2-yl-methyl)
174 2,2,6,6-tetramethylpiperidin-4-ylamino
869,000
175 N(CH3)(4-carboxyphenyl)
1,055,000
176 N(CH3)(4-benzenesulfonylaminocarbonyl-
3,231,000
phenyl
177 N(CH3)CH2 CH2 N(CH3)(4-cyanobenzyl)
2,201,000
178 N(CH3)CH2 CH2 N(CH3)(4-methylbenzyl)
1,870,000
179 N(CH3)CH2 CH2 N(CH3)(3-cyanobenzyl)
2,448,000
180 N(CH3)CH2 CH2 N(CH3)(4-trifluoro-
905,000
methylbenzyl
181 N(CH3)CH2 CH2 N(CH3)(3-trifluoromethyl-
564,000
benzyl)
182 N(CH3)CH2 CH2 (CH3)(4-fluorobenzyl)
2,137,000
183 NHCH(CH3)PH(O)OH 977,000
184 L-lysine ((α-N) 755,000
185 N(CH3)CH2 CH2 N(CH3)(cyclopropylmethyl)
1,787,000
186 N(CH3)CH2 CH(Ph)N(CH3)2
1,053,000
187 N(CH3)2 1,749,000
188 N(CH3)CH2 Ph 1,837,000
189 N(CH3)(1-benzyl-3-piperidinyl)
1,879,000
190 NHOCH2 Ph 1,797,000
191 N(3-picolyl)CH2 CH2 N(CH3)CH2 Ph
2,538,000
192 N(CH3)CH2 CH2 N(CH3)(4-methoxybenzyl)
1,785,000
193 N(4-picolyl)CH2 CH2 N(CH3)CH2 Ph
2,243,000
194 N(2-picolyl)CH2 CH2 N(CH3)CH2 Ph
2,473,000
195 N(CH3)CH2 CH2 N(CH3)(2,4-dimethylbenzyl)
1,119,000
196 N(CH3)CH2 CH2 (2,6-dimethyl-4-morpholinyl)
1,530,000
197 NH2 1,638,000
198 NHCH3 1,825,000
199 4-morpholinyl 2,376,000
200 cis-2,6-dimethyl-4-morpholinyl
1,837,000
201 NHCH2 CH2 CH2 CH3
2,460,000
202 N(CH3)CH2 CH2 N(CH3)C(NCN)NHPh
1,763,000
203 N(CH3)CH2 CH2 N(CH3)(3-fluorobenzyl)
1,262,000
204 N(CH3)CH2 CH2 N(CH3)(2-chlorobenzyl)
1,591,000
205 N(CH3)CH2 CH2 N(CH3)(3-methoxybenzyl)
1,911,000
206 N(CH3)CH2 CH2 N(CH3)(3,5-dimethoxy-
1,735,000
benzyl)
207 3,4-dihydro-6,7-dimethoxy-2-(1H)iso-
2,698,000
quinolinyl
208 N(CH3)(1-benzyl-4-piperidinyl)
1,948,000
209 L-lysine (ε-N) 929,000
210 N(CH3)CH2 CH2 N(CH3)(2-adamantyl)
2,132,000
211 N(CH3)(4-piperidinyl) 85,000
212 5-Methyl-2,5-diazabicyclo[2.2.1]hept-2-yl
860,000
213 N(CH3)CH2 CO2 H
984,000
214 N(CH3)CH2 CH2 CH2 N(CH3)CH2 CH3
1,099,000
215 N(CH3)(1-methyl-4-piperidinyl)
1,283,000
216 N(CH3)(1-propyl-4-piperidinyl)
1,312,000
217 N(CH3)(1-ethyl-4-piperidinyl)
1,422,000
218 N(CH3)CH2 CH(CH3)N(CH3)CH2 Ph
2,123,000
219 N(CH3)CH2 CH(CH3)N(CH3)2
1,588,000
220 N(CH3)CH2 CH2 N(CH3)(bicyclo[2.2.1]-
1,874,000
hept-2-yl)
221 N(CH3)CH2 CH2 NH(2-adamantyl)
3,010,000
222 N(CH3)CH2 CH2 N(CH3)(6,6-dimethylbicyclo-
2,288,000
[3.1.1]hept-2-yl
223 N(CH3)CH2 CH2 N(CH3)(bicyclo[3.2.1]-
2,584,000
oct-2-yl)
224 NH(t-Bu)
225 N(CH3)CH2 CH2 N(CH3)(1-cyclohexen-1-yl)
1,839,000
226 N(CH3)CH2 CH2 NHC(CH3)2 CHCH2
1,309,000
227 2- S-carboxamido-1-pyrrolidinyl
931,000
228 2-hydroxymethyl-1-piperidinyl
50,000
229 3-dimethylamino-1-pyrrolidinyl
1,336,000
230 N(CH3)CH2 CH2 N(CH3)(cyclohexylmethyl)
231 N(CH3)CH2 CH2 N(CH2 CHCH2)C(CH3)2
CHCH2 925,000
232 N(CH3)CH2 CH2 N(CH3)(4-ethylcyclohexyl)
2,476,000
233 N(CH3)CH2 CH2 N(CH3)(2-ethylcyclohexyl)
2,030,000
234 N(CH3)CH2 CH2 N(CH3)(4-methylcyclohexyl)
2,166,000
235 N(CH3)CH2 CH2 N(CH3)(cyclohexyl)
1,952,000
236 N(CH3)CH2 CH2 N(CH3)CH2 CO2 H.TFA
31,000
237 N(CH3)CH2 CH2 N(CH3)CH2 C(O)N(CH3)
2 2,679,000
238 3-dimethylamino-1-azetidinyl
239 1-diphenylmethyl-3-azetidinyl
240 N(CH)CH2 CH2 N(CH3)(cyclohexylmethyl)
3,003,000
241 NHCH2 CH2 N(Et)CH2 CH2 OCH3
1,090,000
______________________________________
TABLE 5
______________________________________
##STR25##
No. R Kobs/[I]
______________________________________
242 CH3 1,700,000
243 4-fluorophenyl 7,486,000
244 3-chlorophenyl 2,453,000
245 phenyl 5,276,000
246 benzyl 5,171,000
247 H 1,100,000
248 i-Pr 2,392,000
249 i-Bu 2,476,000
250 CH2 CO2 Et
1,571,000
251 CH2 CO2 H
1,947,000
252 Et 2,324,000
253 Pr 1,768,000
254 2-pyrimidinyl 2,142,000
255 CH2 CH2 OC(O)NHCH3
2,548,000
256 Cyclopropyl 3,587,000
256a CH2 CH2 OH
2,000,000
______________________________________
TABLE 6
______________________________________
##STR26##
No. n A Kobs/[I]
______________________________________
257 1 NH2 2,342,000
258 1 4-morpholinyl 1,785,000
259 1 N(CH3)CH2 CH2 N(CH3)2
2,522,000
260 0 N(CH3)CH2 CH2 N(CH3)2
3,317,000
261 0 N(Et)2 3,207,000
262 0 N(CH3)(n-Bu) 3,125,000
263 0 4-methyl-1-piperazinyl
3,805,000
264 0 N(CH3)CH2 CH2 N(CH3)CH2 Ph
3,427,000
265 0 4-cyclopropyl-1-piperazinyl
4,500,000
265a 0 1-piperazinyl 3,250,000
265c 0 4-(2-hydroxyethyl)-1-piperazinyl
4,800,000
265d 0 4-morpholinyl 3,700,000
______________________________________
TABLE 7
______________________________________
##STR27##
No. n R4 A Kobs/[I]
______________________________________
266 1 H 4-morpholinyl 169,000
267 1 H N(Et)2 334,000
268 1 H N(CH3)CH2 CH2 N(CH3)2
142,000
269 1 CH3
NH2 637,000
270 1 CH3
N(Et)2 740,000
271 1 CH3
N(n-Pr)2 826,000
272 0 Et N(CH3)CH2 CH2 N(CH3)2
2,423,000
273 0 Et N(CH3)(n-Bu)
3,258,000
______________________________________
TABLE 8
______________________________________
##STR28##
No. n R3 A Kobs/[I]
______________________________________
274 1 H NH2 430,000
275 1 H N(CH3)CH2 CH2 N(CH3)2
290,000
276 1 H OCH3 440,000
277 0 H N(CH3)CH2 CH2 N(CH3)2
548,000
278 0 R OCH2 CH2 N(CH3)2
135,000
279 0 H N(Et)2 566,000
280 0 H 4-morpholinyl 577,000
______________________________________
TABLE 9
__________________________________________________________________________
##STR29##
No.
n R3 R2 A Kobs/[I]
__________________________________________________________________________
281
1 H CO2 H 4-morpholinyl 62,000
282
1 H CO2 CH2 CH2 N(CH3)2
4-morpholinyl 421,000
283
1 H CON(CH3)CH2 CH2 N(CH3)2
4-morpholinyl 393,000
284
1 H OH N(CH3)CH2 CH2 N(CH3).su
b.2 309,000
285
1 H OCH3 N(CH3)CH2 CH2 N(CH3).su
b.2 566,000
286
0 H CON(CH3)2
N(CH3)CH2 CH2 N(CH3).su
b.2 551,000
287
0 H CO2 H N(CH3)CH2 CH2 N(CH3).su
b.2 113,000
288
0 H CH2 OH N(CH3)CH2 CH2 N(CH3).su
b.2 854,000
289
1 H OCH3 N(CH3)CH2 CH2 N(CH3).su
b.2 754,000
290
0 H OCH3 N(CH3)CH2 CH2 N(CH3).su
b.2 1,010,000
291
0 OCH3 H N(CH3)CH2 CH2 N(CH3).su
b.2 1,754,000
292
1 CH2 OCON(Et)2
CH3 4-morpholinyl 807,000
293
1 CON(n-Pr)2
CH3 N(Et)2 457,000
294
1 CON(n-Pr)2
CH3 4-morpholinyl 255,000
295
0 H CN N(CH3)CH2 CH2 N(CH3).su
b.2 846,000
296
0 H OEt N(CH3)CH2 CH2 N(CH3)CH.
sub.2 Ph 776,000
297
0 H 2-(4-morpholinocarbonylphenyl)
N(CH3)CH2 CH2 N(CH3)CH.
sub.2 Ph 1,077,000
298
0 H OCH3 4-methyl-1-piperazinyl
1,845,000
299
0 H Cl N(CH3)CH2 CH2 N(CH3).su
b.2 1,475,000
300
0 H Cl N(CH3)CH2 CH2 N(Et)2
1,282,000
301
0 H Cl N(CH3)CH2 CH2 N(i-Pr)2
1,497,000
302
0 H Cl N(CH3)CH2 CH2 N(CH3)CH.
sub.2 Ph 1,462,000
303
0 OCH3 CH3 N(CH3)CH2 CH2 N(CH3).su
b.2
__________________________________________________________________________
TABLE 10
______________________________________
##STR30##
No. R2 R6 A Kobs/[I]
______________________________________
304 CH3
CH3
OCH2 CH2 N(CH3)2
563,000
305 CH3
CH3
OCH2 CH2 N(Et)2
749,000
306 CH3
CH3
OCH2 CH2 N(i-Pr)2
612,000
307 CH3
CH3
N(CH3)CH2 CH2 N(CH3)2
352,000
308 CH3
CH3
N(CH3)CH2 CH2 N(Et)2
377,000
309 CH3
CH3
N(Et)CH2 CH2 N(CH3)2
398,000
310 H OH N(CH3)CH2 CH2 N(CH3)2
838,000
______________________________________

Enzyme Assays for the Inhibition of Human Polymorphonuclear Leukocyte Elastase Via Hydrolysis of N-t-Boc-alanyl-alanyl-prolylalanine-p-nitroanilide (Boc-AAPAN) or N-t-Boc-alanyl-prolylvaline-p-nitroanilide (Boc-AAPVN) Reagent:

0.05M TES (N-tris[hydroxymethyl]methyl-2-mino-ethanesulfonic acid) Buffer, pH 7.5.

0.2 mM Boc-AAPAN or Boc-AAPVN.

To prepare substrate, the solid was first dissolved in 10.0 ml DMSO. Buffer at pH 7.5 was then added to a final volume of 100 ml.

Crude extract of human polymorphonuclear leukocytes (PMN) containing elastase activity.

Inhibitors (azetidinones) to be tested dissolved in DMSO just before use.

To 1.0 ml of 0.2 mM Boc-AAPAN in a cuvette, 0.01-0.1 ml of DMSO with or without inhibitor was added. After mixing, a measurement was taken at 410 mμ to detect any spontaneous hydrolysis due to presence of test compound. 0.05 Milliliters of PMN extract was then added and the ΔOD/min at 410 mμ was measured and recorded. Beckman model 35 spectrophotometer was used.

Results were expressed to the nearest thousand k obs/I which is the second order rate constant in per mole per second for inactivation of the enzyme.

The elastase activity in the crude PMN extract may vary from one preparation to another. A control of each new batch is run, and the volume added in the assay procedure is adjusted according to activity.

This invention also relates to a method of treating inflammation in patients using a compound of Formula (I), particularly a preferred compound as the active constituent.

It has been found that the compounds of Formula (I) are effective inhibitors of the proteolytic function of human neutrophil elastase.

Accordingly, the compounds of Formula (I), can be used to reduce inflammation and/or relieve pain in diseases such as emphysema, rheumatoid arthritis, osteoarthritis, gout, bronchial inflammation, chronic or acute bronchitis, cystic fibrosis, adult respiratory distress syndrome, atherosclerosis, sepsis, septicemia, shock, periodontitis, glomerular nephritis or nephosis, myocardial infarction, reperfusion injury, infectious arthritis, rheumatic fever and the like, and may reduce hemorrhage in acute promyelocytic leukemia and the like.

In this capacity, and as appreciated by those of skill in the art, therapy comprising administration of compounds of Formula I may actually include co-administration of one or more additional active agents. Classes of active agents include, but are not limited to β2 -adrenergic agonists; anti-cholinergic agents; steroids; non-steroidal anti-inflammatory agents (NSAID's); mucolytic agents; most all stabilizers; and antibacterials.

For purposes of this specification, β2 -adrenergic agonists are intended to include, but are not limited to, metaproterenol, terbutaline, isoetharine, albuterol, and ritodrine, carbuterol, fenoterol, quinterenol, rimiterol, salmefamol, soterenol, and tretoquinol.

For purposes of this specification, anti-cholinergic agents are intended to include, but are not limited to, attopine, and iptratropium-bromide.

For purposes of this specification, mucolytic agents are intended to include, but are not limited to acetylcysteine and guattenesin.

For purposes of this specification, steroids are intended to include, but are not limited to, prednisone, beclomethasone, budesonide, solumedrol, triamcinolone, and methyl-prednisolone.

For purposes of this specification most cell stabilizers are intended to include, but are not limited to cromolyn and ketotafin.

For purposes of this specification, nonsteroidal anti-inflammatory agents are intended to include, but are not limited to aspirin, diflunisal, naphthylsalicylate, phenylbutazolone, oxyphenbutazolone, indomethacin, sulindac, mefenamic acid, meclofenamate sodium, tolmetin, ibuprofen, naproxen, fenoprofen and piroxicam.

For the purposes of this specification, antibacterial agents are intended to include the broad classes of penicillins, cephalosporins and other beta-lactams, aminoglycosides, quinolones, macrolides, tetracyclines, sulfonamides, lincosamides and polymyxins. The penicillins, in turn, are intended to include, but are not limited to penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, floxacillin, ampicillin, ampicillin/sulbactam, amoxicillin, amoxicillin/clavulanate, hetacillin, cyclacillin, bacampicillin, carbenicillin, carbenicillin indanyl, ticarcillin, ticarcillin/clavulanate, azlocillin, mezlocillin, peperacillin, and mecillinam. The cephalosporins and other beta-lactams are intended to include, but are not limited to cephalothin, cephapirin, cephalexin, cephradine, cefazolin, cefadroxil, cefaclor, cefamandole, cefotetan, cefoxitin, ceruroxime, cefonicid, ceforadine, cefixime, cefotaxime, moxalactam, ceftizoxime, cetriaxome, ceftizoxime, cetriaxone, cephoperazone, ceftazidime, imipenem and aztreonam. The aminoglycosides are intended to include, but are not limited to streptomycin, gentamicin, tobramycin, amikacin, netilmicin, kanamycin and neomycin. The quinolones are intended to include, but are not limited to nalidixic acid, norfloxacin, enoxacin, ciprofloxacin, ofloxacin, sparfloxacin and temafloxacin. The macrolides are intended to include, but are not limited to erythomycin, spiramycin and azithromycin. The tetracyclines are intended to include, but are not limited to doxycycline, minocycline and tetracycline. The sulfonamides are intended to include, but are not limited to sulfanilamide, sulfamethoxazole, sulfacetamide, sulfadiazine, sulfisoxazole and co-trimoxazole (trimethoprim/sulfamethoxazole). The lincosamides are intended to include, but are not limited to clindamycin and lincomycin. The polymyxins (polypeptides) are intended to include, but are not limited to polymyxin B and coilstin.

Alternatively, compounds of Formula I are useful in the treatment of certain cancers including nonlymphoblastic leukemias, acute myelogenous leukemia (FAB M1 and FAB M2), acute promyelocytic leukemia (FAB M3), acute myelomonocytic leukemia (FAB M4), acute monocyte leukemia (FAB M5), erythroleukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic monocytic leukemia and conditions associated with leukemia involving activity of PMN neutral proteases e.g. disseminated intravascular coagulation.

Similarly, compounds of Formula I are useful for the inhibition of proteinase 3/myeloblastin, inhibition of elastase, inhibition of proliferation of leukemia cells, inducing differentiation of leukemia cells and remission of the disease state of leukemia.

Moreover, as described above, such treatment may optionally comprise the co-administration of an agent such as a compound selected from the group consisting of epsilon-aminocaproic acid, heparin, trasylol, prednisolone, cytosine arabinoside, b-mercaptopurine, cytarabine, an anthracycline and a vitamin A derivative such as retinoic acid.

For each of the uses, the compounds of Formula (I) and optional treatment agents, may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit Formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, dogs, cats, etc., the compounds of the invention are effective in the treatment of humans.

For treatment as described above the compounds of Formula (I) may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit Formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, dogs, cats, etc., the compounds of the invention are effective in the treatment of human.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparation. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono-oleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate. The said aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspension may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oils, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial. esters derived from fatty acids and hexitol anhydrides, for example sorbitan mono-oleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution glucose in water and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of Formula (I) may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the anti-inflammatory agents are employed.

The amount of active ingredient(s) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 5 mg to 2000 mg or 5000 mg of each active agent(s) compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. For purposes of this specification, this broad dosage range is specifically intended to include, but is not limited to, range of 5 mg to 2000 mg; 25 mg to 2000 mg; 5 mg to 1000 mg; 25 mg to 1000 mg; 5 mg to 500 mg; and 25 mg to 500 mg. Dosage unit forms will generally contain between from about 25 mg to about 500 mg of active ingredient(s).

Furthermore, it is also possible that most effective treatment may warrent administration of an initial dosage of one range (e.g. 1-5 mg of active agent per kg of patient weight) followed by administration of a second range (e.g. 0.1 to 1 mg of active agent per kg of patient weight).

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

The following example illustrates the preparation of the compounds useful in the method of treatment of the present invention, but does not limit the scope of the invention. Starting materials may be optionally prepared as disclosed in EPO 337 549 published Oct. 18, 1989 which is hereby incorporated by reference. Where appropriate, compounds may be produced and used in the form of pharmaceutically acceptable salts. For example, the basic compounds may be used in the form of a hydrochloride or mesylate or other acceptable salt. See Preformulation in Remington's Pharmaceutical Sciences, Mack Publishing, Easton Pa. ##STR31##

The glycolic acid derivatives described herein can be prepared according to the following scheme. The starting acid (as carboxylate anion) may be alkylated (Ex 1A) with a suitably protected α-halo acetic acid derivative to give the glycolate ester 4 which can be deprotected (Ex 1B) to the glycolic acid ester 5. Treatment of 5 with an amine utilizing a condensing agent such as dicyclohexylcarbodiimide or carbomyldiinidazole (Ex 2) affords the deserved amide 6. Alternately, the starting acid 1 may be converted to its acid chloride 2 (Ex 3A) and treated with a suitably protected α-hydroxyalkanoic acid (Ex 3B) in the presence of base to give the protected ester 7. Deprotection (Ex 4), followed by conversion to the acid chloride and treatment with the appropriate amine (Ex 5) affords the desired amide 9.

EXAMPLE 1

A. t-Butoxycarbonylmethyl [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)-carbonyl)-4 -oxo-2-azetidinyl)oxy)benzoate.

To a solution of 0.806 gm of [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl)-4- oxo-2-azetidinyl)oxy)benzoic acid in ∼3 ml DMF is added 0.23 gm. triethylamine followed by 0.50 gm of t-butyl bromoacetate and the mixture stirred overnight at room temperature. Ethyl acetate (25 ml) is then added and the resultant mixture is washed with 2×10 ml water, 10 ml saturated sodium bicarbonate, and 20 ml brine. The organic layer is dried through sodium sulfate and concentrated in vacuo. Chromatography on Silica gel 60 (350 ml column) and elution with 10% ethyl acetate in hexanes gave 0.67 gm of the t-Butoxycarbonylmethyl [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl)-4- oxo-2-azetidinyl)oxy) benzoate.

In a similar manner can be prepared 2-(dimethylamino)-2-oxoethyl, (S-(R*,S*))-4-((3,3-Diethyl-1-(((1-(4-methyl-phenyl)butyl)amino) carbonyl)-4-oxo-2-azetidinyl)oxy)-benzoate (Compound 6), and 2-(N-methylacetamido)ethyl. {2-(R*,S*)}-4-{{3,3-Diethyl-1-{{{1-(4-methyl-phenyl)butyl}amino}carbonyl}- 4-oxo-2-azetidinyl}oxy}-benzoate, (Compound 7).

B. Carboxymethyl [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methyl-phenyl)butyl)amino)carbonyl)-4 -oxo-2-azetidinyl)oxy)benzoate

To the above ester is added 2 ml of anisole and the resulting mixture is cooled in an ice bath and 5 ml of ice cold trifluoroacetic acid is added. The reaction mixture is stirred cold for three hours then allowed to come to room temperature. After 30 minutes, the reaction mixture is concentrated in vacuo and the residue chromatographed on silica gel 60. Elution with 20% ethyl acetate in hexanes containing 1% acetic acid gives 0.53 gm of desired carboxymethyl [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methyl- phenyl)butyl)amino)carbonyl)-4-oxo-2-azetidinyl)oxy)benzoate.

Compound 2

Analysis: C28 H34 N2 O7 +0.3H2 O Calc: C, 65.19; H, 6.75; N, 5.43. Found: C, 65.30; H, 6.76; N, 5.23

Compound 6

Analysis: C30 H39 N3 O6 +0.5H2 O Calc: C, 65.91; H, 7.38; N, 7.60 Found: C, 65.71; H, 7.63; N, 7.50.

Compound 7

Analysis: C31 H41 N3 O6 +0.6EtOAc Calc: C, 66.35; H, 7.64; N, 6.95 Found: C, 66.52; H, 7.89; N, 6.83.

EXAMPLE 2

2-(bis(2-hydroxyethyl)amino)-2-oxoethyl(S-(R*,S*))-4-((3,3-diethyl-1-(((1-( 4-methyl-phenyl)butyl)amino)carbonyl)-4-oxo-2-azetidinyl)oxy)benzoate.

To a solution of 0.125 gm of the acid from 1B in 2-3 ml of methylene chloride is added 0.050 gm of carbonyldiimidazole. The mixture is stirred for 30 minutes at room temperature at which time 0.060 gm of diethanolamine is added along with 1 ml of DMF and 2 ml of methylene chloride. The resulting mixture is stirred overnight at room temperature then concentrated in vacuo. Silica gel chromatography of the residue using 2.5 to 5.0% methanol in methylene chloride gives 0.123 gm of the desired Compound 3, 2-(bis(2-hydroxyethyl)amino)-2-oxoethyl(S-(R*,S*))-4-((3,3-diethyl-1-(((1- (4-methyl-phenyl)butyl)amino)carbonyl)-4-oxo-2-azetidinyl)oxy) benzoate.

Compound 3

Analysis: C32 H43 N3 O8, +0.4H2 O Calc: C, 63.53; H, 7.30; N, 6.95 Found: C, 63,51; H, 7.45; N, 6.95.

Similarly were prepared

Compound 4

Analysis: C31 H40 N4 O7 Calc: C, 64.12; H, 6.94; N, 9.65 Found: C, 64.12; H, 7.18; N, 9.44

Compound 5

Analysis: C32 H43 N3 O9 +0.3H2 O Calc: C, 62.08; H, 7.09; N, 6.79 Found: C, 61.89; H, 7.39; N, 6.88.

Compound 8

Analysis: C40 H47 N3 O8 Calc: C, 68.85; H, 6.79; N, 6.02 Found: C, 68.79; H, 7.06, N, 5.88.

EXAMPLE 3

Preparation of 1-Methyl-2-oxo-2-(phenylmethoxy)ethyl(2S-(1(S*),R*,(R)))-4-((3,3-diethyl-1 -(((1-(4-methylphenyl)butyl)amino)carbonyl)-4-oxo-2-azetidinyl)oxy)benzoate , Compound 10.

A.

To a solution of 1.0 gm [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl)-4- oxo-2-azetidinyl)oxy)benzoic acid in 10 ml methylene chloride is added 2 ml of oxalyl chloride followed by a catalytic amount of DMF. The reaction is stirred 1 hour at room temperature then concentrated in vacuo to yield the acid chloride which is used as is in the next step.

B.

A solution of the above acid chloride in 10 ml of methylene chloride is cooled in an ice bath and a solution of 1.25 gm benzyl L-lactate and 2.0 gm of triethylamine in 10 ml of methylene chloride is added. The mixture is stirred at room temperature overnight then concentrated in vacuo. Chromatography of the residue on silica gel using methylene chloride as the eluent yields 0.795 of the desired 1-Methyl-2-oxo-2-(phenylmethoxy)ethyl (2S-(1(S,),R*,(R)))-4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)car bonyl)-4-oxo-2-azetidinyl)oxy) benzoate, Compound 10.

Analysis: C36 H42 N2 O7 Calc: C, 70.34; H, 6.89; N, 4.56. Found: C, 70.45; H, 7.05; N, 4.48.

EXAMPLE 4

Preparation of 1-carboxyethyl[S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methyl-phenyl)butyl)ami no)carbonyl)-4-oxo-2-azetidinyl)oxy)benzoate

A mixture of 0.69 gm of the benzylester prepared in Example 3 and 0.2 gm 10% Pd/C in 10 ml of EtOAc is treated with hydrogen at 40 psi. When the reaction is complete the mixture is filtered and concentrated in vacuo to yield 0.56 gm of 1-carboxyethyl [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl)-4- oxo-2-azetidinyl)oxy) benzoate, Compound 11.

Analysis: C29 H36 N2 O7 Calc: C, 66.40; H, 6.92; N, 5.34. Found: C, 66.66; H, 7.26; N, 5.05.

EXAMPLE 5

2-(diethylamino)-1-methyl-2-oxoethyl[S-(R*,S*)]-4-((3,3-diethyl-1-(((1-(4-m ethyl-phenyl)butyl)amino)carbonyl)-4-oxo-2-azetidinyl)oxy) benzoate

The acid (0.250 gm) from Example 4 is treated with oxalyl chloride according to the procedure of Example 3A and the corresponding acid chloride is obtained. This material is dissolved in 5 ml methylene chloride and 0.4 ml of diethylamine added. After 1 hour the reaction mixture is concentrated in vacuo and the residue taken in ethyl acetate and washed with saturated sodium bicarbonate solution. The organic layer is dried through sodium sulfate, concentrated and the residue chromatographed on silica gel. Elution with 5% of ethyl acetate methylene chloride gives Compound 12.

Analysis: C33 H45 N3 O6 Calc: C, 68.37; H, 7.82, N, 7.25 Found: C, 68.40; H, 7.93, N, 7.40.

EXAMPLE 6

(S(R*,S*))-1-(((4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl )-4-oxo-2-azetidinyl)oxy)benzoyl)oxy)acetyl) L-proline,

A.

When benzyl L-lactate is replaced by L-proline benzyl ester hydrochloride and triethylamine in the procedure of Example 3 the corresponding amide with L-proline benzyl ester, Compound 8, is obtained.

Analysis: C40 H47 N3 O8 Calc: C, 68.85; H, 6.79, N, 6.02 Found: C, 68.79; H, 7.06, N, 5.88.

B.

Reduction of the material obtained in Example 6A according to the procedure of Example 4 affords Compound 9.

Analysis: C33 H41 N3 O8 +0.5H2 O Calc: C, 64.27; H, 6.86; N, 6.81. Found: C, 64.49; H, 6.90; N, 6.68.

EXAMPLE 7

[S-(R*,S*)]1-(((4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino) carbonyl-4-oxo-2-azetidinyl)oxy)benzoyl)oxy)acetyl-N-benzyl-L-prolinamide.

Treatment of the acid obtained in Example 6B, Compound 9, with oxalyl chloride according to Example 3A gives the corresponding acid chloride which when treated with benzylamine gives the desired benzyl amide, Compound 19.

Analysis: C40 H48 N4 O7 Calc: C, 68.95; H, 6.94; N, 8.04. Found: C, 68.93, H, 7.02; N, 7.96.

EXAMPLE 8

To a solution of the acid chloride (prepared from 0.55 gm of [S-(R*,S*)]4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl)-4- oxo-2-azetidinyl)oxy)benzoic acid according to the procedure of Example 3A) in 3 ml of methylene chloride is added 0.15 gm of N,N-dimethylaminoethanol. The reaction mixture is stirred overnight at room temperature, concentrated in vacuo, then taken up in ethyl acetate (25 ml) and washed with saturated sodium bicarbonate solution. The organic layer is dried through sodium sulfate and concentrated in vacuo. Silica gel chromatography of the residue using 2.5% methanol in methylene chloride gives 0.59 gm of Compound 1, 2-(dimethylamino)ethyl(S-(R*,S*))-4-((3,3-diethyl-1-(((1-(4-methyl-phenyl) butyl)amino)carbonyl)-4-oxo-2-azetidinyl)oxy)benzoate

Analysis: C30 H41 N3 O5 Calc: C, 68.81; H, 7.89; N, 8.02. Found: C, 68.85; H, 8.09; N, 7.97.

When N,N-dimethylaminoethanolamine is replaced by the appropriate amino alcohols the corresponding esters are obtained.

Compound 13

1-Dimethylamino-2-propyl[S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl )butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoate

Analysis: C31 H43 N3 O5 Calc: C, 69.25; H, 8.06; N, 7.82. Found: C, 68.97; H, 8.01; N, 7.80.

Compound 14

3-Dimethylamino-1-propyl[S-(R*,S,)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl )butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoate

Analysis: C31 H43 N3 O5 Calc: C, 69.25; H, 8.06; N, 7.81. Found: C, 68.85; H, 8.19; N, 7.72.

Compound 16

2-Diethylaminoethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate

Analysis: C32 H45 N3 O6 Calc: C, 69.66; H, 8.22; N, 7.62. Found: C, 69.37; H, 8.41; N, 7.51.

Compound 17

2-(1-[4-morpholino]ethyl) [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate

Analysis: C32 H43 N3 O6 Calc: C, 67.94; H, 7.66; N, 7.43. Found: C, 67.67; H, 7.90; N, 7.26.

Compound 18

4-dimethylaminobutyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate

Analysis: C32 H45 N3 O5 +0.2H2 O Calc: C, 69.21; H, 8.24; N, 7.56. Found: C. 69.35; H, 8.24; N, 7.29.

Compound 20

2-dimethylamino-2-methyl-1-propyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate

Analysis: C32 H45 N3 O5 Calc: C, 69.66; H, 8.22; N, 7.62. Found: C, 69.52; H, 8.47; N, 7.59.

Compound 21

2-(diisopropylamino)ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)butyl]amino]carbonyl]- 4-oxo-2-azetidinyl]oxy]benzoate

Analysis: C34 H49 N3 O5 Calc: C, 70.44; H, 8.52; N, 7.25. Found: C, 70.28;. H, 8.76; N, 7.13.

Compound 22

Benzyl[S-(R*,S*)]-4-[2-[[4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino ]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoyl]oxy]-ethyl]-1-Piperazinecarboxyla te

Analysis: C40 H50 N4 O7 Calc: C, 68.75; H, 7.21; N, 8.02. Found: C, 68.39; H, 7.30; N, 7.84.

Compound 23

2-(dibutylamino)ethyl[S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl)bu tyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoate, yl]oxy]benzoate,

Analysis: C36 H53 N3 O5 Calc: C, 71.14; H, 8.79; N, 6.91. Found: C, 71.00; H, 9.03; N, 6.81.

Compound 24

[S-(R*,S*)]-6-(dimethylamino)hexyl-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl) butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]-benzoate

Analysis: C34 H49 N3 O5 +1H2 O Calc: C, 68.31; H, 8.60; N, 7.03. Found: C, 68.34; H, 8.29; N, 6.86.

Compound 26

2-(4-methyl-1-piperazinyl)ethyl[S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl -phenyl)butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoate,

Analysis: C33 H46 N4 O5 +0.8H2 O Calc: C, 66.82; H, 8.09; N, 9.44. Found: C, 67.28; H, 8.10; N, 8.96.

Compound 28

2-(diphenylamino)ethyl[S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)bu tyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoate,

Analysis: C40 H45 N3 O5 +1.4H2 O Calc: C, 71.40; H, 7.16; N, 6.25. Found: C, 71.62; H, 6.99; N, 5.99.

Compound 29

2-(di-2-propenylamino)ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]carbonyl]-4 -oxo-2-azetidinyl]oxy]benzoate,

Analysis: C34 H45 N3 O5 Calc: C, 70.93; H, 7.88; N, 7.30. Found: C, 71.18; H, 8.06; N, 7.34.

Compound 30

2-(dimethylamino)-2-phenylethyl[S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl phenyl)butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoate,

Analysis: C36 H45 N3 O5 Calc. C, 72.09; H, 7.56; N, 7.00. Found: C, 71.75; H, 7.67; N, 6.70.

Compound 31

2-[methyl(phenylmethyl)amino]ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methyl-phenyl )butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzoate,

When [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methylphenyl) butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]-2,6-dimethyl benzoic acid is used in place of [S(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]carbonyl]-4- oxo-2-azetidinyl]oxy]benzoic acid in the procedure of Example 3A and allowed to react with the appropriate amino alcohols the following esters are obtained.

Compound 304

2-(dimethylamino)ethyl [S,(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]carbonyl]-4 -oxo-2-azetidinyl]oxy]-2,6-dimethyl-benzoate,

Compound 305

2-(diethylamino)ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]carbonyl]-4 -oxo-2-azetidinyl]oxy]-2,6-dimethyl-benzoate,

Compound 306

2-[bis(1-methylethyl)amino]-ethyl [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]carbonyl]-4 -oxo-2-azetidinyl]oxy]-2,6-dimethylbenzoate.

Treatment of the acid [S-(R*,S*)]-4-[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]carbonyl]-4 -oxo-2-azetidinyl]oxy]benzeneacetic acid with oxalyl chloride according to the procedure of Example 3A affords the corresponding acid chloride which when allowed to react with the appropriate amino alcohol according to the procedure of Example 8 gives the following amino esters:

Compound 32

Analysis: C31 H43 N3 O5 Calc: C, 69.25; H, 8.06; N, 7.82. Found: C, 69.02; H, 7.86; N, 7.74.

Compound 33

Analysis: C32 H45 N3 O5 Calc: C, 69.66; H, 8.22; N, 7.62. Found: C, 69.10; H, 8.17; N, 7.50.

Compound 34

Analysis: C33 H47 N3 O5 Calc: C, 70.06; H, 8.38; N, 7.43. Found: C, 69.70; H, 8.41; N, 7.05.

Compound 35

Analysis: C33 H45 N3 O6 Calc: C, 68.37; H, 7.82; N, 7.25. Found: C, 68.55; H, 8.19; 7.08.

Compound 36

Analysis: C32 H45 N3 O5 Calc: C, 69.66; H, 8.22; N, 7.62. Found: C, 69.60; H, 8.49; N 7.55.

EXAMPLE 9

To a solution of 0.247 g of Compound 1 in 2 ml of ethyl acetate is added 0.125 gm of m-chloroperoxy benzoic acid. After 30 minutes at room temperature the reaction mixture is concentrated in vacuo. Chromatography of the residue on silica gel using methylene chloride/methanol/water 85/15/1.5 gives the desired N-oxide Compound 15.

Analysis: C30 H41 N3 O8 +1.4H2 O Calc: 63.79; H, 7.82; N, 7.44 Found: 63.89; H, 7.85; N, 7.27

EXAMPLE 10

[S-(R*,S*)]2-[4-[[[2-(dimethylamino)-ethyl]amino]carbonyl]phenoxy]-3,3-diet hyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide.

To a solution of 0.104 g carbonyldiimidazole in 2 ml methylene chloride is added a solution of 0.227 g of [S-(R*,S*)]-4-((3,3-diethyl-1-((-1-(4-methylphenyl)butylamino)carbonyl)-4- oxo-2-azetidinyl)oxy)benzoic acid in 3 ml methylene chloride. The mixture is stirred at ambient temperature for 30 minutes at which time 0.100 g of N,N-dimethylethylenediamine is added. After Stirring overnight at room temperature the reaction mixture is poured into benzene (50 ml) and washed with water. The organic layer is separated, dried through sodium sulfate and concentrated in vacuo. Silica gel chromatography using 5% methanol in methylene chloride yields 0.160 g of 2-[4-[[[2-(dimethylamino)ethyl]carbonyl]phenoxy]-3,3-diethyl-N-[1-(4-methy lphenyl)butyl]-4-oxo-1azetidinecarboxamide. (Compound 73).

Analysis: C30 H42 N4 O4 +0.4H2 O Calc: C, 68.00; H, 8.14; N, 10.57. Found: C, 68.01; H, 8.18; N, 10.62.

EXAMPLE 11

A. (S-(R*,S*))-4-((3,3-diethyl-1-((1-(4-methylphenyl)butylamino)carbonyl)-4-p henyl)butylamino)carbonyl)-4-oxo-2-azetidinyl)oxy)-benzoyl chloride.

To a solution of 0.150 g of [S-(R*,S,)]4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl)-4- oxo-2-azetidinyl)oxy)benzoic acid in 5 ml methylene chloride containing a catalytic amount of dimethylformamide is added 0.5 ml of oxalyl chloride. The mixture is stirred at room temperature for 30 minutes and then concentrated in vacuo to yield (S-(R*,S*))-4-((3,3-diethyl-1-((1-(4-methyl-phenyl)butylamino(carbonyl)-4- oxo-2-azetidinyl)oxy)-benzoyl chloride.

B. [S-(R*,S*)]-2-[4-[[[2-(dimethylamino)ethyl]methylamino]carbonyl]-phenoxy]- 3,3-diethyl-N-[1-(4-methylphenyl]butyl]-4-oxo-1-azetidinecarboxamide.

The above acid chloride is dissolved in 3 ml methylene chloride and a solution of 0.20 gm of N,N,N'-trimethylethylenediamine in 2 ml methylene chloride is added. The mixture is stirred overnight and then concentrated in vacuo. The residue is extracted between ethyl acetate and saturated sodium bicarbonate solution. The organic layer is dried through sodium sulfate and concentrated in vacuo. Silica gel chromatography of the residue (5% methanol in methylene chloride) affords 0.117 g of [S-(R*,S*)]-2-[4-[[[2-(dimethylamino)ethyl]methylamino]carbonyl]-phenoxy]p henoxy]-3,3-diethyl-N-[1-(4-methylphenyl]butyl]-4-oxo-1-azetidinecarboxamid e. (Compound 75).

Analysis: C31 H44 N4 O4 +0.5H2 O Calc: C, 68.23; H, 8.31; N, 10.27. Found: C, 68.20; H, 8.41; N, 10.10.

When N,N,N'-trimethylethylenediamine of Example 11b is replaced by the appropriate amines, there is obtained the corresponding amides.

1) Compound 76

Analysis: C32 H46 N4 O4 Calc: C, 69.79; H, 8.42; N, 10.17. Found: C, 69.02; H, 8.60; N, 9.54.

2) Compound 77

Analysis: C32 H46 N4 O4 +0.75 H2 O Calc: C, 68.12; H, 8.49; N, 9.93. Found: C, 68.22; H, 8.48; N, 10.17.

3) Compound 78

Analysis: C32 H44 N4 O5 Calc. C, 68.06; H, 7.85; N, 9.92. Found: C, 67.84; H, 8,07; N, 9.62.

4) Compound 79

Analysis: C33 H46 N4 O5 +H2 O Calc: C, 66.42; H, 8.11; N, 9.39. Found: C, 66.73; H, 8.19; N, 9.23.

5) Compound 80

Analysis: C35 H52 N4 O6 Calc: C, 67.28; H, 8.39; N, 8.97. Found: C, 67.08; H, 8.77; 8.41.

6) Compound 81

Analysis: C33 H48 N4 O4 +H2 O Calc: C, 68.01; H, 8.65; N, 9.61. Found: C, 68.42; H, 8.59; N, 9.17.

7) Compound 82

Analysis: C36 H46 N4 O4 +0.5H2 O Calc: C, 71.14; H, 7.79; N, 9.21. Found: C, 71.41; H, 7.68; N, 9.10.

8) Compound 83

Analysis: C32 H46 N4 O4 +1.2H2 O Calc: C, 67.15; H, 8.52; N, 9.79. Found: C, 67.21; H, 8.26; N, 9.47.

9) Compound 84

10) Compound 86

Analysis: C35 H52 N4 O4 Calc: C, 70.91; H, 8.84; N, 9.45. Found: C, 70.37; H, 8.84; N, 8.77.

11) Compound 89

Analysis: C31 H39 N5 O4 +0.7H2 O Calc: C, 66.71; H, 7.29; N, 12.54. Found: C, 66.91; H, 7.40; N, 12.14.

12) Compound 90

Analysis: C33 H46 N4 O4 +0.8H2 O Calc: C, 68.67; H, 8.31; N, 9.70. Found: C, 68.82; H, 8.11; N, 9.70.

13) Compound 91

Analysis: C34 H48 N4 O4 +0.3H2 O Calc: C, 70.11; H, 8.41; N, 9.61. Found: C, 70.17; H, 8.64; N, 9.33.

14) Compound 92

Analysis: C30 H42 N4 O4 +1.2H2 O Calc: C, 66.14; H, 8.22; N, 10.29. Found: C, 66.18; H, 8.12; N, 10.31.

15) Compound 93

Analysis: C32 H44 N4 O6 +0.3H2 O Calc: C, 65.57; H, 7.67; N, 9.56. Found: C, 65.72; H, 7.50; N, 9.34.

16) Compound 94

Analysis: C32 H44 N4 O4 +0.3H2 O Calc: C, 70.04; H, 8.08; N, 10.21. Found: C, 70.34; H, 8.90; N, 8.93.

17) Compound 95

Analysis: C33 H46 N4 O4 +0.5H2 O Calc: C, 69.32; H, 8 28; N, 9.80. Found: C, 69.41; H, 8.25; N, 9.58.

18) Compound 99

Analysis: C38 H54 N4 O4 +1.5H2 O Calc: C, 69.37; H, 8.72; N, 8.51 Found: C, 69.48; H, 8.44; N, 8.36

19) Compound 102

Analysis: C40 H49 N5 O6 +1.0H2 O Calc: C, 67.30; H, 7.20; N, 9.81 Found: C, 67.50; H, 7.24; N, 9.53

20) Compound 104

Analysis: C32 H41 N5 O4 +0.75H2 O Calc: C, 67.04; H, 7.47; N, 12.21. Found: C, 67.16; H, 7.56; N, 11.95.

21) Compound 105

Analysis: C32 H44 N4 O5 +0.5H2 O Calc: C, 66.99; H, 7.91; N, 9.77. Found: C, 67,00; H, 8.25; N, 9.50.

Compound 106

Analysis: C32 H45 N5 O5 +0.8H2 O Calc: C, 64.69; H, 7.90; N, 11.78. Found: C, 64.93; H, 8.25; N, 11.12.

23) Compound 107

Analysis: C31 H44 N3 O6 S+0.3H2 O Calc: C, 61.42; H, 7.41; N, 9.24. Found: C, 61.43; H, 7.54; N, 9.05.

24) Compound 110

Analysis: C35 H44 N4 O4 Calc: C, 71.89; H, 7.58; N, 9.58. Found: C, 71.65; H, 7.55; N, 9.34.

25) Compound 111

Analysis: C34 H42 N4 O4 +0.5H2 O Calc: C, 70.44; H, 7.47, N, 9.66. Found: C, 70.82, H, 7.46; N, 9.20.

26) Compound 113

Analysis: C34 H42 N4 O4 +0.3H2 O Calc: C, 70.88; H, 7.45; N, 9.72. Found: C, 71.12; H, 7.44; N, 9.32.

27) Compound 115

Analysis: C34 H42 N4 O4 +0.7H2 O Calc: C, 69.99; H, 7.50; N, 9.60. Found: C, 70.14, H, 7.63; N, 9.25.

28) Compound 116

Analysis: C34 H46 N4 O4 +1.4H2 O Calc: C, 68.06; H, 8.19; N, 9.33. Found: C, 68.40; H, 8.14; N, 8.87.

29) Compound 117

Analysis: C40 H51 N5 O6 +0.6H2 O Calc: C, 67.79; H, 7.42; N, 9.88. Found: C, 67.81; H, 7.58; N, 9.76.

30) Compound 118

Analysis: C33 H47 N5 O4 +0.7H2 O Calc: C, 67.14; H, 8.26; N, 11.86 Found: C, 67.54; H, 8.51; N, 11.28.

31) Compound 119

Analysis: C35 H48 N4 O4 +1.25H2 O Calc: C, 68.76; H, 8.32; N, 9.16. Found: C, 69.07; H, 8.19; N, 8.75.

32) Compound 121

Analysis: C34 H48 N4 O4 +1H2 O Calc: C, 68.66; H, 8.47; N, 9.42. Found: C, 69.02; H, 8.32; N, 9.06.

33) Compound 125

Analysis: C37 H48 N4 O4 +0.5H2 O Calc: C, 71.47; H, 7.94; N, 9.01 Found: C, 71.65; H, 7.91; N, 8.73.

34) Compound 126

Analysis: C41 H54 N4 O5 +2H2 O Calc: C, 68.83; H, 8.25; N, 7.64. Found: C, 69.03; H, 7.79; N, 7.50.

35) Compound 132

Analysis: C35 H50 N4 O4 Calc: C, 71.15; H, 8.53; N, 9.48. Found: C, 70.90; H, 8.74; 9.12.

36) Compound 133

Analysis: C40 H52 N4 O4 +0.9H2 O Calc: C, 71.80; H, 8.10; N, 8.37. Found: C, 71.86; H, 8.17; N, 8.18.

37) Compound 137

Analysis: C37 H48 N4 O4 +0.8H2 O Calc. C, 70.85; H, 7.97; H, 8.93. Found: C, 71.01; H, 7.97; N, 8.54.

38) Compound 139

Analysis: C39 H51 N5 O4 +0.8H2 O Calc: C, 70.09; H, 7.93; N, 10.48. Found: C, 70.18; H, 7.79; N, 10.42.

39) Compound 142

Analysis: C38 H55 N5 O6 Calc: C, 67.33; H, 8.18; N, 10.33. Found: C, 67.02; H, 8.31; N, 9.89.

40) Compound 143

Analysis: C34 H51 N5 O4 Calc: C, 68.77; H, 8.66; N, 11.80. Found: C, 68.57; H, 8.50; N, 11.53

41) Compound 144

Analysis: C38 H59 N5 O4 +0.4H2 O Calc: C, 69.45; H, 9.17; N, 10.65. Found: C, 69.69; H, 9.02; N, 10 35.

42) Compound 145

Analysis: C36 H47 N5 O4 +H2 O Calc: C, 68.44; H, 7.82; N, 11.08 Found: C, 68.69; H, 7.74; N, 10.76.

43) Compound 148

Analysis: C36 H47 N5 O4 +0.4H2 O Calc: C, 69.62; H, 7.56; N, 11.27. Found: C, 69.79; H, 7.70; N, 11.12.

44) Compound 149

Analysis: C39 H50 N4 O4 +0.4H2 O Calc: C, 72.50; H, 7.93; N, 8.67 Found: C, 72.44; H, 7.99; N, 8.87.

45) Compound 150

Analysis: C36 H47 N5 O4 +0.3H2 O Calc. C, 69.83; H, 7.74; N, 11.31. Found: C, 69.93; H, 7.65, N, 11.10.

46) Compound 151

Analysis: C33 H47 N5 O4 Calc: C, 68.60; H, 8.20; N, 12.12. Found: C, 68.40; H, 8.16; N, 11.90.

47) Compound 245

Analysis: C36 H44 N4 O4 Calc: C, 72.46; H, 7.43; N, 9.39 Found: C, 72.49; H, 7.49; N, 9.25

48) Compound 246

Analysis: C37 H46 N4 O4 +0.25H2 O Calc: C, 72.26; H, 7.61; N, 9.10. Found: C, 72.35; H, 7.83; N, 8.73.

49) Compound 154

Analysis: C35 H48 N4 O4 +0.8H2 O Calc: C, 69.70; H, 8.29; N, 9.29 Found: C, 69.65; H, 8.27; N, 9.35.

50) Compound 158

Analysis: C35 H48 N4 O4 +0.5H2 O Calc: C, 73.29; H, 7.65; N, 8.33. Found: C, 73.71, H, 7.75, N, 7.75.

51) Compound 159

Analysis: C35 H48 N4 O4 Calc: C, 73.09; H, 7.66; N, 8.31. Found: C, 73.40; H, 7.75; N, 7.80.

52) Compound 160

Analysis: C38 H48 N4 O4 +1.0H2 O Calc: C, 70.78; H, 8.12; N, 8.68. Found: C, 71.00; H, 8.05; N, 8.59.

53) Compound 161

Analysis: C43 H52 N4 O4 +1H2 O Calc: C, 73.05; H, 7.70; N, 7.92. Found: C, 73.29; H, 7.95; N, 7.37.

54) Compound 166

Analysis: C33 H46 N4 O4 +1.5H2 O Calc. C, 67.20; H, 8.37; N, 9.50 Found: C, 67.38; H, 7.98; N, 9.41.

55) Compound 171

Analysis: C36 H52 N4 O6 +1.6H2 O Calc: C, 64.95; H, 8.36; N, 8.41. Found: C, 65 26; H, 8.15; N, 8.07.

56) Compound 177

Analysis: C38 H47 N5 O4 Calc: C, 71.56; H, 7.43; N, 10,98. Found: C, 71 64; H, 7.62; 10.93.

57) Compound 178

Analysis: C38 H50 N4 O4 Calc: C, 72.81; H, 8.04; N, 8.94. Found: C, 72.96;H, 8.17;N, 8.83.

58) Compound 179

Analysis: C38 H47 N5 O4 Calc: C, 71.56; H, 7.43; N, 10.98. Found: C, 72.00; H, 7.55;N 10.87.

59) Compound 180

Analysis: C38 H47 F3 N4 O4 Calc: C, 67.04; H, 6.96; N, 8.23. Found: C, 67.02; H, 7.25;N, 8.23.

60) Compound 181

Analysis: C38 H47 F3 N4 O4 Calc: C, 67.04; H, 6.96; N, 8.23 Found: C, 66.63; H, 6.98; N, 7.94.

61) Compound 182

Analysis: C37 H47 F N4 O4 Calc: C, 70.45; H, 7.51; N, 8.88 Found: C, 70.28; H, 7.74;N, 8.82.

62) Compound 185

Analysis: C34 H48 N4 O4 Calc: C, 70.80; H, 8.39; N, 9.71 Found: C, 70.44; H, 8.45; N, 9.51.

63) Compound 186

Analysis: C37 H48 N4 O4 +0.8H2 O Calc: C, 70.85; H, 7.97; N, 8.93 Found: C, 71.12; H, 8.25; N, 8.45.

64) Compound 191

Analysis: C42 H51 N5 O4 +0.5CH2 Cl2 Calc: C, 69.78; H, 7.16; N, 9.58 Found: C, 69.75; H, 7.31; N, 9.68.

65) Compound 203

Analysis: C37 H47 N4 O4 +1.1H2 O Calc: C, 68.31; H, 7.62; N, 8.61 Found: C, 68.32; H, 7.57; N, 8.53.

66) Compound 204

Analysis: C37 H47 ClN4 O4 Calc: C, 68.66; H, 7.32; N, 8.66. Found: C, 68.32, H, 7.48; N, 8.42.

67) Compound 205

Analysis: C38 H50 N4 O5 +0.7H2 O Calc: C, 69.63; H, 7.90; N, 8.54. Found: C, 69.72; N, 7.91; N, 8.54.

68) Compound 206

Analysis: C39 H52 N4 O6 +0.8H2 O Calc: C, 68.15; H, 7.86; N, 8.15 Found: C, 68.01; H, 8.02; N, 8.15.

EXAMPLE 12

A) [S-(R*,S*)]3,3-Diethyl-2-[4-[[[2-(4-hydroxy-1-piperidinyl)ethyl]amino]carb onyl]phenoxy]-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide

When 1-(2-aminoethyl)-4-benzyloxypiperidine is used in place of N,N,N'-trimethylethylene diamine in the procedure of Example 11b there is obtained [S-(R*,S*)]3,3-diethyl-2-[4-[[[2-(4-benzyloxy-1-piperidinyl]ethyl]amino]ca rbonyl]phenoxy]-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide.

B) [S-(R+,S*)]-3,3-diethyl-2-[4-[[[2-(4-hydroxy-1-piperidinyl)ethyl]amino]car bonyl ]phenoxy]-N-[1-(4-methyl-phenyl)butyl]-4-oxo-1-azetidine-carboxamide

A solution of the amide from step A above in 10 ml of glacial acetic acid containing 22 mg of 10% Pd/C is hydrogenated under 42 lb hydrogen pressure. When TLC-indicate completion of the reaction, the mixture is filtered and concentrated in vacuo after the addition of 50 ml toluene. The residue is dissolved in ethyl acetate, washed with saturated sodium bicarbonate solution. The organic layer is dried with sodium sulfate and concentrated in vacuo. The residue is chromatographed on 15 g silica gel using 5% methanol in methylene chloride and yields 96 mg of

[S-(R+,S*)]-3,3-diethyl-2-[4-[[[2-(4-hydroxy-1-piperidinyl)ethyl]amino]carb onyl]phenoxy]-N-[1-(4-methyl-phenyl)butyl]-4-oxo-1-azetidine-carboxamide

Analysis: C33 H46 N4 O5 +1.3H2 O Calc: C, 65.83; H, 8.13; N, 9.30 Found: C, 66.10; H, 8.06; N, 8.91

When 1-(2-aminoethyl )-4-benzyloxypiperidine is replaced in the procedure of Example 12 by the appropriate amines, the following compounds 123, 124, 129,131 and 138 are obtained, for example:

1) Compound 129

Analysis: C34 H48 N4 O5 Calc: C, 68.89; H, 8.16; N, 9.45 Found: C, 68.68; H, 8.18; N, 8.65

2) Compound 131

Analysis: C32 H44 N4 O5 +1H2 O Calc: C, 65.92; H, 7.96; N, 9.61 Found: C, 66.07; H, 7.86; N, 9.45

3) Compound 138

Analysis: C33 H46 N4 O5 +0.5H2 O Calc: C, 67.43; H, 8.06; N, 9.53 Found: C, 67.61; H, 8.06; N, 9.37

Diamine Intermediates

The diamines used to prepare the amino amides described herein were commercially available or prepared according to the following routes ##STR32##

EXAMPLE 13

A. N-cyanomethylhomopiperazine.

To a solution of 1.98 g homopiperazine in 50 ml acetone is added 4.25 g of powdered anhydrous sodium carbonate and 1.3 ml of chloroacetonitrite. After 24 hrs the reaction mixture is filtered and the filter cake washed with 100 ml acetone. The combined filtrates are concentrated in vacuo and the residue chromatographed on silica gel using methylene chloride as the eluent. The yield of N-cyanomethyl homopiperazine is 2.69 g.

B. N-(2-aminoethyl)homopiperazine.

To a suspension of 1.02 g lithium aluminum hydride in 50 ml of ether is slowly added a solution of 2.65 gm N-cyanomethyl homopiperazine in 25 ml ether. After the addition in complete the mixture is heated at reflux for 1 hour, then cooled to room temperature and quenched carefully with 1 ml water, 1 ml of 15% sodium hydroxide solution and 3 ml water. The mixture is filtered through sodium sulfate, the filter cake washed well with ether and the combined filtrates concentrated in Vacuo to yield 2.60 g. N-(2-aminoethyl)homopiperazine. ##STR33##

EXAMPLE 14
PAC N-(2-methylaminoethyl)homopiperazine

A). N-(2-formamidoethyl)homopiperazine.

To a carefully prepared solution of 0.718 g of 60% sodium hydride dispension in 75 ml of absolute ethanol which has been cooled to 0° C. is added 7.3 ml of ethyl formate. After 5 minutes there is added a solution of 2.55 gm of N-(2-aminoethyl)homopiperazine in 25 ml absolute ethanol. The mixture is stirred at room temperature overnight. Saturated sodium bicarbonate solution (15 ml) is then added and the reaction mixture is stirred with 150 ml ethyl acetate, filtered through MgSO4 and the filtrate concentrated in vacuo. Chromatography of the residue on 150 gm silica gel using an eluent of methylene chloride/methanol/conc. ammonium hydroxide (95/5/0.5) gives 2.78 g of N-(2-formamidoethyl)homopiperazine.

B). N-(2-methylaminoethyl)homopiperazine.

To a solution of 2.75 gm of N-(2-formamidoethyl)homopiperazine in 20 ml of dry THF under N2 is added carefully 60 ml of borane THF solution. After the addition is complete the reaction mixture is heated to reflux for 5 hours then stirred at room temperature overnight. The reaction mixture is quenched by the careful addition of 20 ml of 6N HCl followed by refluxing for 1 hour. The reaction mixture is cooled, 50 ml of water added and solid KOH added carefully to alkaline pH. Extraction with ether gives the desired product N-(2-methylamino) homopiperazine.

EXAMPLE 15 ##STR34## A) N-benzyl-N,N'-dimethyl-N'-(2-phenylethyl)ethylenediamine

A mixture of 0.900 gm N-benzyl-N,N'-dimethylethylenediamine, 1.10 gm powdered sodium carbonate and 0.75 ml of 2-phenylethylbromide is refluxed for 5 hours. An additional 0.25 ml of bromide is added during this time. The reaction mixture is then cooled and filtered. The filterate is concentrated in vacuo and the residue chromatographed on silica gel using an eluent of CH2 Cl2 /CH3 OH/NH4 OH (97/3/0.3) to yield 0.875 gm of N-benzyl-N,N'-dimethyl-N'-(2-phenylethyl)ethylenediamine.

B) N,N'-dimethyl-N-(2-phenylethyl)ethylenediamine.

To a solution 0.870 gm N-benzyl-N-N'-dimethyl-N'-(2-phenylethyl)ethylenediamine in 10 ml ethanol and 5 ml acetic acid is added 0.18 gm Pd (OH)2 /C. The mixture is hydrogenated at 40 psi for 3.5 hours, then filtered and concentrated in vacuo. The residue is made akaline with 1N NaOH and extracted well with ethyl acetate (5×25 ml). The combined extracts are filtered through sodium sulfate and concentrated to yield N,N'-dimethyl-N-(2-phenylethyl)ethylenediamine.

EXAMPLE 16 ##STR35## A)

A solution of 1.28 gm 1-(2-amino-ethyl)piperidine and 1.07 gm pyridine-3-carboxaldehyde in 40 ml of toluene is heated to reflux under a Dean Stark trap. After 10 ml toluene distilled over the NMR of an aliquot indicated no aldehyde left. The reaction mixture was concentrated and the imine used directly in the next step.

B)

To a suspension of 0.380 gm of lithium aluminum hydride in 30 ml of dry THF which has been cooled to -10°C is added dropwise a solution of the above imine in 20 ml of dry THF. After about 1 hour the cold reaction mixture is quenched by the addition of 5 ml of 5N NaOH, then diluted with 100 ml ether and 20 ml of water. The organic layer is separated, washed with brine, filtered thru sodium sulfate and concentrated to give 2.17 gm of 1-[2-(3-pyridylmethylamino)ethyl]-piperidine suitable for use in subsequent reactions.

EXAMPLE 17 ##STR36##

To 7.50 gm of N,N'-dimethylethylenediamine which has been cooled in an ice-ethanol bath is added portionwise over a 30 minute period 1.40 gm of 3-picolyl chloride. After stirring cold for 1 hour after the addition is completed, the reaction mixture is concentrated in vacuo and the residue partitioned between 50 ml of ether and 10 ml of 5N NaOH solution. The organic layer is separated and the aqueous layer extracted 2 times with 50 ml of ether. The combined organic extracts are dried through sodium sulfate and concentrated in vacuo. Chromatography on 150 gm silica gel using CH2 Cl2 /CH3 OH/NH4 OH (90/10/1) as eluent gives 0.930 g of N,N'-dimethyl-N-(3-pyridylmethyl)ethylenediamine.

EXAMPLE 18

Amino Acid→diamine

A) To an ice cooled solution of 2.29 N-CBZ-D-Prolinein 50 ml of CHCl2 is added 1.35 gm 1-hydroxybenzotriazole hydrate followed by 2.06 gm of dicyclohexylcarbodiimide. After 20 minutes, 0.85 ml of pyrrolidine is added and the reaction mixture stirred overnight after which time it is filtered and the filtrate concentrated in vacuo. The residue is partitioned between 100 ml ethyl acetate and 50 ml of 2N hydrochloric acid. The organic layer is separated, washed with 50 ml of 1.0N sodium hydroxide solution, dried through sodium sulfate and concentrated in vacuo. Chromatography on 150 gm of silica gel using ethylacetate in hexanes (30-100%) as eluent gives 2.04 gm of the desired pyrrolidine amide

B) To a solution of 1.519 gm of the amide (prepared in A) in 20 ml absolute ethanol is added 75 mg of 10% Pd on carbon catalyst. The mixture is hydrogenated at 40 psi for about an hour then filtrate and the filtrate concentrated to yield D-proline pyrrolidine amide.

C) To a suspension of 0.380 gm of lithium aluminum hydride in 15 ml of dry tetrahydrofuran is carefully added a solution of the D-proline amide (prepared in B above) in 10 ml tetrahydrofuran. The mixture is refluxed for 2 hrs then cooled and quenched with 2 ml of 2.5N sodium hydroxide. The mixture is filtered through a pad of sodium sulfate and the filter cake washed with 2×50 ml of ether. The combined filtrates are concentrated in vacuo to yield 0.80 gm of desired 2-(1-pyrrolidinylmethyl) pyrrolidine.

EXAMPLE 19

[S-(R*,S*)]-2-[4-[[(4-Methyl)piperazin-1-yl]carbonyl]phenoxy]((3,3-diethyl- N-[1-(methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide

A solution of S-(R*,S*)]-4-(((3,3-diethyl-1-((4-methylphenyl)butylamino)carbonyl)-4-oxo- 2-azetidinyl)oxy)benzoyl chloride (3.8 mmol), prepared as in Example 11A, in 50 ml of methylene chloride was cooled in an ice bath and a solution of 0.70 gm of N-methylpiperazine in 10 ml of methylene chloride was added over 5 min. The reaction was stirred for 1 hr and was then poured into a mixture of ice water and 10% potassium carbonate. The product was extracted with two portions of methylene chloride and each methylene chloride layer was washed with a portion of brine. The methylene chloride layers were combined, dried over sodium sulfate and evaporated. The residue was purified with flash chromatography using ethyl acetate, then 2% triethylamine/10% methanol/88% ethyl acetate to afford 2.1 gm of the title compound as a white solid.

Analysis: C30 H42 N4 O4 Calc: C, 69.64; H, 7.92; N, 10.48 Found: C, 69.62; H, 8.23; N, 10.46

EXAMPLE 20

[S-(R*,S*)]-2-[4-[[(4-Methyl)piperazin-1-yl]carbonyl]phenoxy]-((3,3-diethyl -N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide

When [S-(R*,S*)]-4-(((3,3-diethyl-1-((3,4-methylenedioxyphenyl)butylamino)carbo nyl)-4-oxo-2-azetidinyl)oxy)benzoyl chloride (3.1 mmol), prepared as in Example 11A, was reacted with N-methylpiperazine as in Example 19, there was obtained 1.75 gm of the title compound.

Analysis: C31 H40 N4 O6 Calc: C, 65.94; H, 7.14; N, 9.92 Found: C, 65.80; H, 7.31; N, 10.05

EXAMPLE 21

[S-(R*,S*)]-2-[4-[[(4-Hydroxyethyl)piperazin-1-yl]carbonyl]phenoxy]-((3,3-d iethyl-N-[1-(methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide

When [S-(R*,S*)]-4-(((3,3-diethyl-1-((4-methylphenyl)butylamino)carbonyl)-4-oxo -2-azetidinyl)oxy)benzoyl chloride (3.8 mmol), prepared as in Example 11A, was reacted with N-(2-hydroxyethyl)piperazine (7.6 mmol) and diisopropylethylamine (3.8 mmol) as in Example 19, there was obtained 2.1 gm of the title compound.

Analysis: C32 H44 N4 O5 Calc: C, 68.06; H, 7.85; N, 9.92 Found: C, 67.88; H, 7.87; N, 10.17

EXAMPLE 22

[S-(R*,S*)]-2-[4-[[(4-Hydroxyethyl)piperazin-1-yl]carbonyl]phenoxy]-((3,3-d iethyl-N-[1-(3,4-methylene dioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide

When [S-(R*,S*)]-4-(((3,3-diethyl-1-((3,4-methylenedioxyphenyl)butylamino)carbo nyl)-4-oxo-2-azetidinyl)oxy)benzoyl chloride (3.1 mmol), prepared as in Example 11A, was reacted with N-(2-hydroxyethyl)piperazine (6.2 mmol) and diisopropylethylamine (3.1 mmol) as in Example 19, there was obtained 1.50 gm of the title compound.

Analysis: C32 H42 N4 O7.1.5H2O Calc: C, 61.94; H, 6.89; N, 9.06 Found: C, 61.95; H, 6.92; N, 8.96

EXAMPLE 23

[S-(R*,S*)]-2-[4-[[(4-Cyclopropyl)piperazin-1-yl]carbonyl]phenoxy]-((3,3-di ethyl-N-[1-(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide

To a solution of [S-(R*,S*)]-4-(((3,3-diethyl-1-((4-methylphenyl)butylamino)carbonyl)-4-oxo -2-azetidinyl)oxy)benzoyl chloride (3.8 mmol), prepared as in Example 11A, in 50 ml of methylene chlorine was added N-(cyclopropyl)piperazine dihydrochloride (5.7 mmol) and then a solution of diisopropylethylamine (15.8 mmol) in 10 ml of methylene chloride was added over 5 min with ice-bath cooling. The reaction was stirred for 1 hr at 0 C and then poured into ice water. The product was extracted with two portions of methylene chloride and each methylene chloride layer was washed with a portion of brine. The methylene chloride layers were combined, dried over sodium sulfate and ethyl acetate/50% hexanes, then 70% ethyl acetate/30% hexanes to afford 2.1 gm of the title compound as a white solid.

Analysis: C32 H42 N4 O4 Calc: C, 70.69; H, 7.91; N, 9.99 Found: C, 70.62; H, 8.04; N, 9.95

EXAMPLE 24

[S-(R*,S*)]-2-[4-[[(4-Cyclopropyl)piperazin-1-yl]carbonyl]phenoxy]-((3,3-di ethyl-N-[1-(3,4-methylene dioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide

When [S-(R*,S*)]-4-(((3,3-diethyl-1-((3,4-methylenedioxyphenyl)butylamino)carbo nyl)-4-oxo-2-azetidinyl)oxy)benzoyl chloride (3.1 mmol), prepared as in Example 11A, was reacted with N-(cyclopropyl)piperazine (4.6 mmol) and diisopropylethylamine (9.3 mmol) as in Example 23, there was obtained 1.80 gm of the title compound.

Analysis: C32 H42 N4 O7 Calc: C, 67.10; H, 7.17; N, 9.49 Found: C, 67.03; H, 7.31; N, 9.47

EXAMPLE 25

[S-(R*,S*)]-2-[4-[[(4-Piperazin-1-yl)carbonyl]phenoxy]-((3,3-diethyl-N-[1-( 4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide

Step A: [S-R*,S*)]-2-[4-[[(4-(t-Butoxycarbonyl))piperpazin-1-yl]carbonyl]phenoxy]- ((3,3-diethyl-N-[(4-methylphenyl)butyl]-4-oxo-1-azetidinecarboxamide

[S-(R*,S*)]-4-(((3,3-Diethyl-1-((4-methylphenyl)butylamino)carbonyl)-4-oxo- 2-azetidinyl)oxy)benzoyl chloride (0.4 mmol), prepared as in Example 11A, was reacted with N-(t-butoxycarbonyl )piperazine (0.6 mmol) and triethylamine (1.2 mmol) as in Example 23. The crude, title product so obtained was used directly in the following Step B.

Step B: [S-R*,S*)]-2-[4-[(Piperazin-1-yl)carbonyl]phenoxy]-((3,3-diethyl-N-[1-(4-m ethylphenyl)butyl-4-oxo-1-azetidinecarboxamide

The product from Step A was dissolved in 0.5 ml anisole and 2 ml of cold TFA was added. The reaction was stirred at 0 C for 1 hr and was then diluted with methylene chloride and evaporated. The residue was taken up in methylene chloride, washed with 10% sodium carbonate and brine, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography using 5, then 10% methanol/methylene chloride to afford 0.212 gm of title product.

Analysis: C30 H40 N4 O5.1H2 O Calc: C, 66.89; H, 7.85; N, 10.40 Found: C, 67.06; H, 7.55; N, 10.30

EXAMPLE 26
PAC [S-(R*,S*)]-2-[4-[[(4-Piperazin-1-yl)carbonyl]phenoxy]-((3,3-diethyl-N-[1-( 3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide

Step A: [S-R*,S*)]-2-[4-[[(4-Benzyloxycarbonyl) Piperazin-1-yl]carbonyl]phenoxy]-((3,3-diethyl-N-[1-3,4-methylenedioxyphen yl)butyl]-4-oxophenyl)butyl]-4-oxo-1-azetidinecarboxamide

When [S-(R*,S*)]-4-(((3,3-diethyl-1-((3,4-methylenedioxphenyl)butylamino)carbon yl)-4-oxo-2-azetidinyl)oxy)benzoyl chloride (0.41 mmol), prepared as in Example 11A, was reacted with N-(benzyloxycarbonyl)piperazine (0.77 mmol) and diisopropylethylamine (1.6 mmol) as in Example 23, there was obtained 290 mg of the title compound.

Step B. [S-R*,S*)]-2-[4-[(Piperazin-1-yl)carbonyl]phenoxy]-((3,3-diethyl-N-[1-(3,4 -methylenedioxyphenyl)butyl-4-oxo-1-azetidinecarboxamide

A solution of 250 mg of material from Example 26, Step A in 10 ml of ethanol was hydrogenated at 40 p.s.i. over 50 mg of 10% Pd/C for 16 hrs. The reaction was filtered and evaporated. The residue was purified by preparative TLC eluting with 2% TEA/10% methanol/88% ethyl acetate to afford 150 mg of title product.

Analysis: C30 H38 N4 O6.3H2O Calc: C, 59.59; H, 7.33; N, 9.29 Found: C, 59.66; H, 7.65; N, 9.61

INVENTORS:

MacCoss, Malcolm, Mills, Sander G., Finke, Paul E., Doherty, James B., Dorn, Conrad P., Shah, Shrenik K., Durette, Philippe L., Sahoo, Soumya P., Hagmann, William K., Hale, Jeffrey J., Lanza, Thomas J.

THIS PATENT IS REFERENCED BY THESE PATENTS:
Patent Priority Assignee Title
11603396, May 22 2019 ORNA THERAPEUTICS, INC Circular RNA compositions and methods
11679120, Dec 04 2019 ORNA THERAPEUTICS, INC Circular RNA compositions and methods
11766449, Dec 04 2019 ORNA THERAPEUTICS, INC Circular RNA compositions and methods
11771715, Dec 04 2019 ORNA THERAPEUTICS, INC Circular RNA compositions and methods
11802144, May 22 2019 ORNA THERAPEUTICS, INC Circular RNA compositions and methods
11845950, Jun 06 2018 Massachusetts Institute of Technology Circular RNA for translation in eukaryotic cells
6194569, Aug 31 1998 Bristol-Myers Squibb Pharma Company Efficient process for the preparation of [S-(R,S)]-N-[1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2[4-[4-methyl-1-piper azinyl)carbonyl]phenoxy]-4-oxo-1-azetidine carboxamide, a human leukocyte elastase inhibitor
6348209, Dec 30 1996 ZIVENA, INC Formulation and method for treating neoplasms by inhalation
6419900, Dec 30 1996 ZIVENA, INC Formulation and method for treating neoplasms by inhalation
6419901, Dec 30 1996 ZIVENA, INC Method for treating neoplasms by inhalation
6471943, Dec 30 1996 ZIVENA, INC Formulation and method for treating neoplasms by inhalation
THIS PATENT REFERENCES THESE PATENTS:
Patent Priority Assignee Title
4064120, Nov 01 1976 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
4115382, Jun 06 1977 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having basic substituents
4166907, Nov 01 1976 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
4174317, Mar 24 1978 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives
4260743, Dec 13 1978 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
4510086, Nov 06 1980 Hoechst Aktiengesellschaft 2(4-Allylthioazetidin-2-on-1-yl)acetic acid ester compounds
4534896, Jun 13 1983 E R SQUIBB & SONS, INC , A CORP OF DE 3-Acylamino-2-oxoazetidine-1-(β-oxopropionic acid)
4559335, Oct 03 1983 E R SQUIBB & SONS, INC , A CORP OF DE 3-Acylamino-1-carboxymethyloxy (or thio) carbonyl-2-azetidinones
4576749, Oct 03 1983 E R SQUIBB & SONS, INC , A CORP OF DE 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
4680391, Dec 01 1983 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
5229381, Dec 11 1983 Merck Sharp & Dohme Corp Substituted azetidinones as anti-inflammatory and antidegenerative agents
AT295547,
AT375640,
DE1945542,
DE2046822,
DE2046823,
DE2748827,
DE2824554,
DE2911589,
DE3007298,
EP23097,
EP42026,
EP76621,
EP199630,
EP267723,
EP337549,
EP481671,
EP337549,
EP481671,
GB1192952,
GB1604752,
GB2093839,
WO9300332,
ASSIGNMENT RECORDS    Assignment records on the USPTO
///////////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Dec 17 1992LANZA, THOMAS J , JR MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992HALE, JEFFREY J MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992SAHOO, SOUMYA P MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992SHAH, SHRENIK K MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992MILLS, SANDER G MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992MACCOSS, MALCOLMMERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992HAGMANN, WILLIAM K MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992FINKE, PAUL E MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992DURETTE, PHILIPPE L MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992DORN, CONRAD P MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 17 1992DOHERTY, JAMES B MERCK & CO , INC ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079890884 pdf
Dec 16 1993Merck & Co., Inc.(assignment on the face of the patent)
Nov 02 2009MERCK & CO , INC Merck Sharp & Dohme CorpCHANGE OF NAME SEE DOCUMENT FOR DETAILS 0238540563 pdf
Apr 26 2012Merck Sharp & Dohme CorpSchering CorporationMERGER SEE DOCUMENT FOR DETAILS 0288500515 pdf
May 02 2012Schering CorporationMerck Sharp & Dohme CorpCHANGE OF NAME SEE DOCUMENT FOR DETAILS 0288660511 pdf
MAINTENANCE FEES AND DATES:    Maintenance records on the USPTO
Date Maintenance Fee Events
Mar 15 1999ASPN: Payor Number Assigned.
Jun 21 2000M183: Payment of Maintenance Fee, 4th Year, Large Entity.
Jun 09 2004M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Jul 09 2004ASPN: Payor Number Assigned.
Jul 09 2004RMPN: Payer Number De-assigned.
Jun 27 2008M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jan 07 20004 years fee payment window open
Jul 07 20006 months grace period start (w surcharge)
Jan 07 2001patent expiry (for year 4)
Jan 07 20032 years to revive unintentionally abandoned end. (for year 4)
Jan 07 20048 years fee payment window open
Jul 07 20046 months grace period start (w surcharge)
Jan 07 2005patent expiry (for year 8)
Jan 07 20072 years to revive unintentionally abandoned end. (for year 8)
Jan 07 200812 years fee payment window open
Jul 07 20086 months grace period start (w surcharge)
Jan 07 2009patent expiry (for year 12)
Jan 07 20112 years to revive unintentionally abandoned end. (for year 12)